



**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07H 21/02, 21/04, C12N 5/10, 5/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/12519</b> <b>(43) International Publication Date:</b> 9 June 1994 (09.06.94)
<b>(21) International Application Number:</b> PCT/US93/09636 <b>(22) International Filing Date:</b> 8 October 1993 (08.10.93)  <b>(30) Priority Data:</b> 07/980,518 25 November 1992 (25.11.92) US  <b>(71) Applicant:</b> BRIGHAM AND WOMEN'S HOSPITAL [US/US]; 75 Francis Street, Boston, MA 02115 (US).  <b>(72) Inventors:</b> BIRKENBACH, Mark; 17301 Briar Drive, Tinley Park, IL 60477 (US). KIEFF, Elliot; 269 Lee Street, Brookline, MA 02146 (US).  <b>(74) Agents:</b> FOX, Samuel, L. et al.; Sterne, Kessler, Goldstein & Fox, 1100 New York Avenue, N.W., Suite 600, Washington, DC 20005-3934 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> EPSTEIN BARR VIRUS INDUCED GENES  <b>(57) Abstract</b>  The present invention relates, in general, to Epstein Barr virus induced (EBI) genes. In particular, the present invention relates to DNA segments coding for EBI 1, EBI 2 or EBI 3 polypeptides; EBI 1, EBI 2 or EBI 3 polypeptides; recombinant DNA molecules; cells containing the recombinant DNA molecules; antisense EBI 1, EBI 2, or EBI 3 constructs; antibodies having binding affinity to an EBI 1, EBI 2 or EBI 3 polypeptide; hybridomas containing the antibodies; nucleic acid probes for the detection of the presence of Epstein Barr Virus; a method of detecting Epstein Barr virus in a sample; and kits containing nucleic acid probes or antibodies.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## Epstein Barr Virus Induced Genes

### STATEMENT OF GOVERNMENT RIGHTS IN THE INVENTION

Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government has certain rights in this invention.

### BACKGROUND OF THE INVENTION

#### *Field of the Invention*

The present invention relates, in general, to Epstein Barr virus induced (EBI) genes. In particular, the present invention relates to DNA segments coding for EBI 1, EBI 2, or EBI 3 polypeptides; EBI 1, EBI 2, or EBI 3 polypeptides; recombinant DNA molecules; cells containing the recombinant DNA molecules; antisense EBI 1, EBI 2, or EBI 3 constructs; antibodies having binding affinity to an EBI 1, EBI 2, or EBI 3 polypeptide; hybridomas containing the antibodies; nucleic acid probes for the detection of the presence of Epstein Barr Virus; a method of detecting Epstein Barr virus in a sample; and kits containing nucleic acid probes or antibodies.

#### *Background Information*

Epstein-Barr Virus (EBV) is the cause of infectious mononucleosis, a benign proliferation of infected B lymphocytes (Henle, G., *et al.*, *Proc. Natl. Acad. Sci. USA* 59(1):94-101 (1968)) and can also cause acute and rapidly progressive B lymphoproliferative disease in severely immune compromised patients or in experimental infection of tamarins (Miller, G., *Fields Virol.*, 2nd ed., 1921-58 (1990)). Infection of human B lymphocytes, *in vitro*, results in expression of six virus encoded nuclear proteins (EBNAs) and two virus encoded membrane proteins (LMPs) (Kieff and Liebowitz, *Fields Virol.*, 2nd ed., 1889-1920 (1990)), and in substantially altered cell growth (Nilsson and

Klein, *Adv. Cancer Res.* 37(319):319-80 (1982)). EBV infected B lymphocytes recapitulate features of antigen stimulation in enlarging, increasing RNA synthesis, expressing activation antigens and adhesion molecules, secreting Ig and proliferating (Boyd, A.W., *et al.*, *J. Immunol.* 134(3):1516-23 (1985); Gordon, J., *et al.*, *Immunology* 58(4):591-5 (1986); 5 Guy and Gordon, *Intl. J. Cancer* 43(4):703-8 (1989); Nilsson and Klein, *Adv. Cancer Res.* 37(319):319-80 (1982); Thorley-Lawson, D.A., *et al.*, *J. Immunol.* 134(5):3007-12 (1985)). Unlike antigen stimulated B lymphocytes, EBV infected B lymphocytes continue to proliferate *in vitro* as 10 immortalized lymphoblastoid cell lines (LCLs) (Nilsson, K., *et al.*, *Intl. J. Cancer* 8(3):443-50 (1971)).

EBV effects on lymphocytes have been studied by comparing the properties of EBV-negative [EBV(-)] Burkitt lymphoma (BL) cell lines and EBV-positive [EBV(+)] derivatives, infected by EBV, *in vitro* (Calender, A., 15 *et al.*, *Proc. Natl. Acad. Sci. USA* 84(22):8060-4 (1987); Ehlin-Henriksson, B., *et al.*, *Intl. J. Cancer* 39(2):211-8 (1987); Nilsson and Klein, *Adv. Cancer Res.* 37(319):319-80 (1982); Rowe, M., *et al.*, *Intl. J. Cancer* 37(3):367-73 (1986)). EBV(-) BL cells resemble proliferating centroblasts of germinal centers, characteristically expressing CD10, CD20, CD77 (BLA), class II 20 antigen, and the carbohydrate recognized by peanut agglutinin (Calender, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 84(22):8060-4 (1987); Ehlin-Henriksson, B., *et al.*, *Intl. J. Cancer* 39(2):211-8 (1987); Favrot, M.C., *et al.*, *Intl. J. Cancer* 38(6):901-6 (1986); Gregory, C.D., *et al.*, *Intl. J. Cancer* 42(2):213-20 (1988); Gregory, C.D., *et al.*, *J. Gen. Virol.* 71:1481-1495 (1990); 25 Gregory, C.D., *et al.*, *J. Immunol.* 139(1):313-8 (1987); Rowe, M., *et al.*, *Intl. J. Cancer* 37(3):367-73 (1986); Rowe, M., *et al.*, *Intl. J. Cancer* 35(4):435-41 (1985)). Both EBV(-) BL cells and centroblasts lack surface IgD and antigens associated with early phases of mitogen stimulation *in vitro*, including CD23, CD39 and CD30. In general, EBV(+) BL cells closely 30 resemble EBV infected primary B lymphocytes in not expressing CD10 or CD77 and in expressing early activation and differentiation markers, vimentin,

Bac-1, Bcl-2, surface IgD and CD44 (Calender, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 84(22):8060-4 (1987); Ehlin-Henriksson, B., *et al.*, *Intl. J. Cancer* 39(2):211-8 (1987); Favrot, M.C., *et al.*, *Intl. J. Cancer* 38(6):901-6 (1986); Gregory, C.D., *et al.*, *J. Gen. Virol.* 71:1481-1495 (1990); Henderson, S., *et al.*, *Cell* 65(7):1107-15 (1991); Rowe, M., *et al.*, *Intl. J. Cancer* 37(3):367-73 (1986); Rowe, M., *et al.*, *EMBO J.* 6(9):2743-51 (1987); Spira, G., *et al.*, *J. Immunol.* 126(1):122-6 (1981); Suzuki, T., *et al.*, *J. Immunol.* 137(4):1208-13 (1986)). Experiments with single gene transfer into EBV(-) B lymphoma cells, or with specifically mutated EBV recombinants reveal that EBNA 2, LMP 1 and EBNA 3C are essential for lymphocyte growth transformation and alter cellular or viral gene expression. Expression of EBNA 2 alone in EBV(-) BL cell lines results in enhanced transcription of CD23, CD21 (Cordier, M., *et al.*, *J. Virol.* 64(3):1002-13 (1990); Wang, F., *et al.*, *J. Virol.* 64(5):2309-18 (1990); Wang, F., *et al.*, *Proc. Natl. Acad. Sci. USA* 84(10):3452-6 (1987)), and c-fgr (Knutson, J.C., *J. Virol.* 64(6):2530-6 (1990)). EBNA 2 also transactivates the LMP promoters (Fahraeus, R., *et al.*, *Proc. Natl. Acad. Sci. USA* 87(19):7390-4 (1990); Wang, F., *et al.*, *J. Virol.* 64(7):3407-16 (1990)). Analysis of a series of EBNA 2 mutants indicates that the ability of EBNA 2 to transactivate gene expression is tightly linked to its essential role in cell growth transformation (Cohen, J.I., *et al.*, *J. Virol.* 65(5):2545-54 (1991)). LMP 1 is also critical to EBV's effects on cell growth. LMP 1 transforms immortalized rodent fibroblasts (Baichwal and Sugden, *Oncogene* 2(5):461-7 (1988); Wang, D., *et al.*, *Cell* 43:831-40 (1985)) and induces vimentin, Bcl-2 and many of the activation markers and adhesion molecules that EBV induces in BL cells (Birkenbach, M., *et al.*, *J. Virol.* 63(9):4079-84 (1989); Henderson, S., *et al.*, *Cell* 65(7):1107-15 (1991); Wang, D., *et al.*, *J. Virol.* 62(11):4173-84 (1988)). In EBV(-) BL cells, EBNA 3c induces higher level expression of CD21 (Wang, F., *et al.*, *J. Virol.* 64(5):2309-18 (1990)).

Since altered B lymphocyte gene expression is a central theme in EBV induced changes in B lymphocyte growth, a more complete description of the

5 repertoire of EBV induced genes would be advantageous prior to the investigation of specific genes for their role as mediators of EBV effects on cell growth. Also, because of the similar effects of EBV and antigen, EBV induced genes are likely to include mediators of antigen induced B lymphocyte growth or differentiation. Previously, recognition of such genes has been largely based on increased expression of lymphocyte surface markers (Calender, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 84(22):8060-4 (1987)), defined by monoclonal antibodies derived against EBV or antigen activated B lymphocytes. Few of these surface markers are likely candidates for important effectors of EBV or antigen induced alterations in lymphocyte growth. The experiments described here use subtractive hybridization to identify cDNA clones of RNAs which are more abundant in an *in vitro* infected EBV(+) BL cell than in the non-infected EBV(-) control BL cell.

#### SUMMARY OF THE INVENTION

15 It is a general object of this invention to provide EBI 1, EBI 2, and EBI 3 DNA segments. It is a specific object of this invention to provide a DNA segment coding for a polypeptide having an amino acid sequence corresponding to an EBI 1, EBI 2, or EBI 3 polypeptide.

20 It is another object of the invention to provide a substantially pure polypeptide having an amino acid sequence corresponding to an EBI 1, EBI 2, or EBI 3 polypeptide.

It is a further object of the invention to provide a nucleic acid probe for the detection of the presence of Epstein Barr Virus in a sample.

25 It is another object of the invention to provide a method of detecting Epstein Barr Virus in a sample.

It is a further object of the invention to provide a kit for identifying or amplifying a gene encoding an EBI 1, EBI 2, or EBI 3 polypeptide.

It is another object of the invention to provide a DNA molecule comprising, 5' to 3', a promoter effective to initiate transcription in a cell and an EBI 1, EBI 2, or EBI 3 DNA segment.

5 It is a further object of the invention to provide a recombinant DNA molecule comprising a vector and an EBI 1, EBI 2, or EBI 3 DNA segment.

It is a further object of the invention to provide a DNA molecule comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding an amino acid sequence corresponding to an EBI 1, EBI 2, or EBI 3 polypeptide, and a transcriptional  
10 termination region functional in said cell.

It is another object of the invention to provide cells containing the above-described DNA molecules.

It is a further object of the invention to provide an antibody having binding affinity to an EBI 1, EBI 2, or EBI 3 polypeptide, or a binding  
15 fragment thereof.

It is another object of the invention to provide a hybridoma which produces the above-described antibody, or binding fragment thereof.

It is a further object of the invention to provide a method of detecting an EBI 1, EBI 2, or EBI 3 polypeptide in a sample.  
20

It is another object of the invention to provide a diagnostic kit comprising EBI 1, EBI 2, or EBI 3 antibodies.

Further objects and advantages of the present invention will be clear from the description that follows.

### ***BRIEF DESCRIPTION OF THE DRAWINGS***

25 ***Figure 1.*** EBV induced gene (EBI) 1 and 2 RNA: Nucleotide and deduced amino acid sequences. (A) EBI 1 has two potential translational initiation codons. In frame stop codons are indicated asterisks (\*). A hydrophobic amino terminal segment (single underline) is predicted to be a signal peptide for membrane translocation. Seven other highly hydrophobic

segments are predicted to form membrane spanning domains and are delineated by double underlines. Potential asparagine linked glycosylation sites (CHO#####) are present in the extracellular amino terminal segment and third extracellular loop. The sequence motif S-(I/V)-D-R-(Y/F)-X-X-X-X (where X represents consecutive hydrophobic residues), is highly conserved among a large number of G-protein coupled receptors and is indicated at the end of the third transmembrane domain (::::). (B) EBI 2 has 2 possible initiator methionine codons. Predicted transmembrane domains are indicated (double underlines). No signal peptide sequence was identified. The amino terminal extracellular segment contains a potential N-linked glycosylation site (CHO#####).

**Figure 2.** RNA blot hybridization analysis of EBV induced cellular gene expression. Polyadenylated (4 to 12  $\mu$ g per lane) was size fractionated on formaldehyde agarose gels, transferred to charged nylon membranes, and hybridized with the probes indicated at the bottom of each autoradiograph panel. RNA samples used are indicated at the top of each lane (LCL:EBV immortalized primary B lymphoblastoid cell line, IB4; BL:EBV negative Burkitt lymphoma cell line, BL41; EBL:EBV infected Burkitt lymphoma cell line, BL41/B95-8, derived by *in vitro* infection of BL41 line). Dashes indicate positions of ribosomal RNA bands (18s, 28s). The band detected at 1.5 kb in the LCL lane by the P68 probe is due to residual signal from a prior hybridization.

**Figure 3.** Expression of EBI 1 and EBI 2 receptor genes in human lymphoid tissues and cell lines. <sup>32</sup>P-labelled probes indicated at the left of each panel were hybridized to blots containing RNA from the cell lines indicated at the top of each lane. BL41 and BL30 are EBV-negative BL cell lines; BL41/P3HR1 is infected with a non-transforming EBV strain, p3HR1; BL41/B95-8 is infected with a transforming EBV strain; IB4 is a cell line derived by infecting primary B lymphocytes with EBV of the B95-8 strain; LCL-W91 is a recently established cell line transformed with EBV strain W91; TONSIL is unfractionated cells from surgically excised human tonsil; PBMC



is unfractionated peripheral blood mononuclear cells; PBMC PWM is PBMC stimulated 72 h with pokeweed mitogen (2.5  $\mu\text{g/ml}$ ); PBT PHA is T cells purified from PBMC by sheep erythrocyte rosetting, stimulated 72 h with phytohemagglutinin (1  $\mu\text{g/ml}$ ); B MARR is post-mortem bone marrow; SPLEEN is unfractionated cells from surgically excised spleen; HL60 is a promyelocytic leukemia cell line; U937 is a monocytic leukemia cell line; K562 is a chronic myelogenous leukemia cell line; JURKAT is a T cell leukemia cell line; HSB-2 is a T cell acute lymphoblastic leukemia cell line; RHEK-1 is an adenovirus/SV40 transformed human keratinocyte; TK143 is an osteosarcoma cell line. Each panel is a composite prepared from autoradiographs of two separate blots for each probe.

*Figure 4.* EBI 1 and EBI 2 gene expression in human tissues. EBI 1, EBI 2 and immunoglobulin mu chain (IgU) probes were hybridized to RNA samples from the following human tissues: heart (HE), brain (BR), placenta (PL), lung (LU), liver (LI), kidney (KI), skeletal muscle (SM) and pancreas (PA). Numbers at the left indicate positions and sizes (in kb) of RNA markers. Specific RNA bands are indicated by arrows to the right of each panel. The EBI 1 probe detects faint 2.4 kb bands in lung and pancreas PNA. The EBI 2 probe detects an abundant 1.9 kb RNA in lung, and a faint 1.9 kb band in pancreas. The 2.7 kb IgU RNA is detected in lung, liver and pancreas preparations. The 1.5 kb band in placental RNA hybridized with IgU probe is residual signal from a previous hybridization.

*Figure 5.* Complete nucleotide and deduced amino acid sequences of EBI 3 cDNA. The 1164 nucleotide EBI 3 cDNA contains a 690 nucleotide open reading frame encoding a 26 kD polypeptide. A hydrophobic amino terminal segment (bold underline) comprises a signal peptide for membrane translocation. No other hydrophobic segments that could potentially form a transmembrane domain are evident. Two potential asparagine-linked glycosylation sites are indicated (CHO###). The nucleotide sequence of the 3' untranslated region bears significant homology with the human Alu repeat element (light underline).

**Figure 6.** RNA blot hybridization analysis of EBI 3 gene expression. Polyadenylated RNA (4 to 12  $\mu$ g/lane) was size fractionated on formaldehyde agarose gel, transferred to an activated nylon membrane and hybridized with a  $^{32}$ P-labeled EBI 3 cDNA, actin and glyceraldehyde dehydrogenase (GAPDH) probes. RNA samples used in each lane are indicated at the top. (LCL is the EBV-immortalized primary B lymphoblastoid cell line, IB4; BL is the EBV-negative Burkitt lymphoma cell line, BL41; -EBL is the EBV-infected Burkitt lymphoma cell line, BL41/B95-8, derived by *in vitro* infection of BL41 line.) An abundant 1.5 kb RNA is recognized by the EBI 3 probe in both EBV-infected cell line RNA samples (LCL, EBL), but is undetectable in the EBV-negative cell sample (BL). Control hybridization with actin and GAPDH probes indicate that the BL lane contains as much or more RNA than the EBV-infected cell lanes. Dashes indicate positions of ribosomal RNA bands (18s, 28s).

**Figure 7.** Expression of EBI 3 gene RNA in human tissues and cell lines.

(A) EBI 3 or actin probes were hybridized to blots containing RNA from the cell lines or lymphoid tissues indicated at the top of each lane. (BL41 and BL30 are EBV(-) Burkitt lymphoma cell lines; BL41/P3HRI is infected with the non-transforming P3HRI strain of EBV; BL41/B95-8 is infected with the transforming, B95-8 strain of EBV; IB4 is a lymphoblastoid cell line generated by transformation of primary B lymphocytes with B95-8 virus; LCL-W91 EBV strain; TONSIL represents unfractionated cells from surgically excised human tonsil; PBMC is unfractionated peripheral blood mononuclear cells; PBMC-PWM is PBMC stimulated 72 h with pokeweed mitogen (2.5  $\mu$ g/ml); PBT-PHA is T cells purified from PBMC by sheep erythrocyte rosetting, stimulated 72 h with phytohemagglutinin (1.0  $\mu$ g/mL); B MARR is post-mortem costal bone marrow; SPLEEN is unfractionated cells from surgically excised normal human spleen; HL60 is a promyelocytic leukemia cell line; U937 is a histiocytic lymphoma cell line with monocyte features; K562 is a chronic myelogenous leukemia cell line; Jurkat is a T cell

leukemia; TK143 is an osteosarcoma line. Each autoradiographic panel was generated from two separate blots.

5 (B) EBI 3 was hybridized to a commercially prepared blot (Multiple Tissue Northern, Clontech, CA) containing polyadenylated RNA (2  $\mu$ g/lane) from each of the following human tissues: heart (HE), brain (BR), placenta (PL), lung (LU), liver (LI), kidney (KI), skeletal muscle (SM) and pancreas (PA). The EBI 3 probe specifically detects an abundant 1.5 kb RNA in the placental RNA preparation (position indicated by arrow). A faint band of similar size is also observed in liver RNA. Numbers at the left indicate  
10 positions and sizes (in kb) of RNA markers.

### DEFINITIONS

In the description that follows, a number of terms used in recombinant DNA (rDNA) technology are extensively utilized. In order to provide a clear and consistent understanding of the specification and claims, including the  
15 scope to be given such terms, the following definitions are provided.

DNA segment. A DNA segment, as is generally understood and used herein, refers to a molecule comprising a linear stretch of nucleotides wherein the nucleotides are present in a sequence that may encode, through the genetic code, a molecule comprising a linear sequence of amino acid residues that is referred to as a protein, a protein fragment or a polypeptide.  
20

Gene. A DNA sequence related to a single polypeptide chain or protein, and as used herein includes the 5' and 3' untranslated ends. The polypeptide can be encoded by a full-length sequence or any portion of the coding sequence, so long as the functional activity of the protein is retained.

25 A "complementary DNA" or "cDNA" gene includes recombinant genes synthesized by reverse transcription of messenger RNA ("mRNA").

Structural gene. A DNA sequence that is transcribed into mRNA that is then translated into a sequence of amino acids characteristic of a specific polypeptide.

Restriction Endonuclease. A restriction endonuclease (also restriction enzyme) is an enzyme that has the capacity to recognize a specific base sequence (usually 4, 5, or 6 base pairs in length) in a DNA molecule, and to cleave the DNA molecule at every place where this sequence appears. For example, *EcoRI* recognizes the base sequence GAATTC/CTTAAG.

Restriction Fragment. The DNA molecules produced by digestion with a restriction endonuclease are referred to as restriction fragments. Any given genome may be digested by a particular restriction endonuclease into a discrete set of restriction fragments.

Agarose Gel Electrophoresis. To detect a polymorphism in the length of restriction fragments, an analytical method for fractionating double-stranded DNA molecules on the basis of size is required. The most commonly used technique (though not the only one) for achieving such a fractionation is agarose gel electrophoresis. The principle of this method is that DNA molecules migrate through the gel as though it were a sieve that retards the movement of the largest molecules to the greatest extent and the movement of the smallest molecules to the least extent. Note that the smaller the DNA fragment, the greater the mobility under electrophoresis in the agarose gel.

The DNA fragments fractionated by agarose gel electrophoresis can be visualized directly by a staining procedure if the number of fragments included in the pattern is small. The DNA fragments of genomes can be visualized successfully. However, most genomes, including the human genome, contain far too many DNA sequences to produce a simple pattern of restriction fragments. For example, the human genome is digested into approximately 1,000,000 different DNA fragments by *EcoRI*. In order to visualize a small subset of these fragments, a methodology referred to as the Southern hybridization procedure can be applied.

Southern Transfer Procedure. The purpose of the Southern transfer procedure (also referred to as blotting) is to physically transfer DNA fractionated by agarose gel electrophoresis onto a nitrocellulose filter paper or another appropriate surface or method, while retaining the relative positions

of DNA fragments resulting from the fractionation procedure. The methodology used to accomplish the transfer from agarose gel to nitrocellulose involves drawing the DNA from the gel into the nitrocellulose paper by capillary action.

5           Nucleic Acid Hybridization. Nucleic acid hybridization depends on the principle that two single-stranded nucleic acid molecules that have complementary base sequences will reform the thermodynamically favored double-stranded structure if they are mixed under the proper conditions. The double-stranded structure will be formed between two complementary single-  
10           stranded nucleic acids even if one is immobilized on a nitrocellulose filter. In the Southern hybridization procedure, the latter situation occurs. As noted previously, the DNA of the individual to be tested is digested with a restriction endonuclease, fractionated by agarose gel electrophoresis, converted to the single-stranded form, and transferred to nitrocellulose paper, making it  
15           available for reannealing to the hybridization probe.

Hybridization Probe. To visualize a particular DNA sequence in the Southern hybridization procedure, a labeled DNA molecule or hybridization probe is reacted to the fractionated DNA bound to the nitrocellulose filter. The areas on the filter that carry DNA sequences complementary to the  
20           labeled DNA probe become labeled themselves as a consequence of the reannealing reaction. The areas of the filter that exhibit such labeling are visualized. The hybridization probe is generally produced by molecular cloning of a specific DNA sequence.

Oligonucleotide or Oligomer. A molecule comprised of two or more  
25           deoxyribonucleotides or ribonucleotides, preferably more than three. Its exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. An oligonucleotide may be derived synthetically or by cloning.

Sequence Amplification. A method for generating large amounts of a  
30           target sequence. In general, one or more amplification primers are annealed

to a nucleic acid sequence. Using appropriate enzymes, sequences found adjacent to, or in between the primers are amplified.

Amplification Primer. An oligonucleotide which is capable of annealing adjacent to a target sequence and serving as an initiation point for DNA synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated.

Vector. A plasmid or phage DNA or other DNA sequence into which DNA may be inserted to be cloned. The vector may replicate autonomously in a host cell, and may be further characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion and into which DNA may be inserted. The vector may further contain a marker suitable for use in the identification of cells transformed with the vector. Markers, for example, are tetracycline resistance or ampicillin resistance. The words "cloning vehicle" are sometimes used for "vector."

Expression. Expression is the process by which a structural gene produces a polypeptide. It involves transcription of the gene into mRNA, and the translation of such mRNA into polypeptide(s).

Expression vector. A vector or vehicle similar to a cloning vector but which is capable of expressing a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences.

Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and may additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.

Functional Derivative. A "functional derivative" of a sequence, either protein or nucleic acid, is a molecule that possesses a biological activity (either functional or structural) that is substantially similar to a biological activity of

the protein or nucleic acid sequence. A functional derivative of a protein may or may not contain post-translational modifications such as covalently linked carbohydrate, depending on the necessity of such modifications for the performance of a specific function. The term "functional derivative" is intended to include the "fragments," "segments," "variants," "analogs," or "chemical derivatives" of a molecule.

As used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, and the like. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, and the like. Moieties capable of mediating such effects are disclosed in *Remington's Pharmaceutical Sciences* (1980). Procedures for coupling such moieties to a molecule are well known in the art.

Fragment. A "fragment" of a molecule such as a protein or nucleic acid is meant to refer to any portion of the amino acid or nucleotide genetic sequence.

Variant. A "variant" of a protein or nucleic acid is meant to refer to a molecule substantially similar in structure and biological activity to either a the protein or nucleic acid, or to a fragment thereof. Thus, provided that two molecules possess a common activity and may substitute for each other, they are considered variants as that term is used herein even if the composition or secondary, tertiary, or quaternary structure of one of the molecules is not identical to that found in the other, or if the amino acid or nucleotide sequence is not identical.

Analog. An "analog" of a protein or genetic sequence is meant to refer to a protein or genetic sequence substantially similar in function to a protein or genetic sequence described herein.

Allele. An "allele" is an alternative form of a gene occupying a given locus on the chromosome.

Mutation. A "mutation" is any detectable change in the genetic material which may be transmitted to daughter cells and possibly even to succeeding generations giving rise to mutant cells or mutant individuals. If the descendants of a mutant cell give rise only to somatic cells in multicellular organisms, a mutant spot or area of cells arises. Mutations in the germ line of sexually reproducing organisms may be transmitted by the gametes to the next generation resulting in an individual with the new mutant condition in both its somatic and germ cells. A mutation may be any (or a combination of) detectable, unnatural change affecting the chemical or physical constitution, mutability, replication, phenotypic function, or recombination of one or more deoxyribonucleotides; nucleotides may be added, deleted, substituted for, inverted, or transposed to new positions with and without inversion. Mutations may occur spontaneously and can be induced experimentally by application of mutagens. A mutant variation of a DNA segment results from a mutation. A mutant polypeptide may result from a mutant DNA segment.

Species. A "species" is a group of actually or potentially interbreeding natural populations. A species variation within a DNA segment or protein is a change in the nucleic acid or amino acid sequence that occurs among species and may be determined by DNA sequencing of the segment in question.

Substantially Pure. A "substantially pure" protein or nucleic acid is a protein or nucleic acid preparation that is generally lacking in other cellular components.

### ***DETAILED DESCRIPTION OF THE INVENTION***

The present invention relates to novel DNA sequences, EBI 1, EBI 2, and EBI 3, which have been identified as Epstein Barr virus induced genes.



A. DNA segments coding for EBI 1, EBI 2, and EBI 3 polypeptides,  
and fragments thereof.

In one embodiment, the present invention relates to a DNA segment coding for a polypeptide having an amino acid sequence corresponding to a polypeptide selected from the group consisting of EBI 1, EBI 2, and EBI 3 polypeptides, or at least 7 contiguous amino acids thereof (preferably, at least 10, 15, 20, or 30 contiguous amino acids thereof). In one preferred embodiment, the DNA segment comprises the sequences set forth in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5; allelic, mutant or species variation thereof, or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 40, or 50 contiguous nucleotides thereof). In another preferred embodiment, the DNA segment encodes an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof, or at least 7 contiguous amino acids thereof (preferably, at least 10, 15, 20, or 30 contiguous amino acids thereof).

Also included within the scope of this invention are the functional equivalents of the herein-described DNA or nucleotide sequences. The degeneracy of the genetic code permits substitution of certain codons by other codons which specify the same amino acid and hence would give rise to the same protein. The DNA or nucleotide sequence can vary substantially since, with the exception of methionine and tryptophan, the known amino acids can be coded for by more than one codon. Thus, portions or all of the EBI 1, EBI 2, or EBI 3 gene could be synthesized to give a DNA sequence significantly different from that shown in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5. The encoded amino acid sequence thereof would, however, be preserved.

In addition, the DNA or nucleotide sequence may comprise a nucleotide sequence which results from the addition, deletion or substitution of at least one nucleotide to the 5'-end and/or the 3'-end of the DNA formula shown in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5 or a derivative

thereof. Any nucleotide or polynucleotide may be used in this regard, provided that its addition, deletion or substitution does not alter the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 which is encoded by the nucleotide sequence. For example, the present invention is intended to include any nucleotide sequence resulting from the addition of ATG as an initiation codon at the 5'-end of the inventive nucleotide sequence or its derivative, or from the addition of TTA, TAG or TGA as a termination codon at the 3'-end of the inventive nucleotide sequence or its derivative. Moreover, the DNA fragment of the present invention may, as necessary, have restriction endonuclease recognition sites added to its 5'-end and/or 3'-end.

Such functional alterations of a given DNA or nucleotide sequence afford an opportunity to promote secretion and/or processing of heterologous proteins encoded by foreign DNA sequences fused thereto. All variations of the nucleotide sequence of the EBI 1, EBI 2, and EBI 3 genes and fragments thereof permitted by the genetic code are, therefore, included in this invention.

Further, it is possible to delete codons or to substitute one or more codons by codons other than degenerate codons to produce a structurally modified polypeptide, but one which has substantially the same utility or activity of the polypeptide produced by the unmodified DNA molecule. As recognized in the art, the two polypeptides are functionally equivalent, as are the two DNA molecules which give rise to their production, even though the differences between the DNA molecules are not related to degeneracy of the genetic code.

#### A.1. Isolation of DNA.

In one aspect of the present invention, DNA segments coding for polypeptides having amino acid sequences corresponding to EBI 1, EBI 2, and EBI 3 are provided. In particular, the DNA segment may be isolated from a biological sample containing RNA or DNA.

The DNA segment may be isolated from a biological sample containing RNA using the techniques of cDNA cloning and subtractive hybridization as previously described (Birkenbach *et al.*, *J. of Virology* 63:9:4079-4084). The DNA segment may also be isolated from a cDNA library using a homologous probe.

The DNA segment may be isolated from a biological sample containing genomic DNA or from a genomic library using techniques well known in the art. Suitable biological samples include, but are not limited to, blood, semen and tissue. The method of obtaining the biological sample will vary depending upon the nature of the sample.

One skilled in the art will realize that the human genome may be subject to slight allelic variations between individuals. Therefore, the isolated DNA segment is also intended to include allelic variations, so long as the sequence is a functional derivative of the EBI 1, EBI 2, or EBI 3 gene.

One skilled in the art will realize that organisms other than humans may also contain EBI 1, EBI 2, or EBI 3 genes (for example, eukaryotes; more specifically, mammals, birds, fish, and plants; more specifically, gorillas, rhesus monkeys, and chimpanzees). The invention is intended to include, but not be limited to, EBI 1, EBI 2, and EBI 3 DNA segments isolated from the above-described organisms.

#### A.2. Synthesis of DNA.

In the alternative, the DNA segment of the present invention may be chemically synthesized. For example, a DNA fragment with the nucleotide sequence which codes for the expression product of an EBI 1, EBI 2, or EBI 3 gene may be designed and, if necessary, divided into appropriate smaller fragments. Then an oligomer which corresponds to the DNA fragment, or to each of the divided fragments, may be synthesized. Such synthetic oligonucleotides may be prepared, for example, by the triester method of

Matteucci *et al.*, *J. Am. Chem. Soc.* 103:3185-3191 (1981) or by using an automated DNA synthesizer.

5 An oligonucleotide may be derived synthetically or by cloning. If necessary, the 5'-ends of the oligomers may be phosphorylated using T4 polynucleotide kinase. Kinasing of single strands prior to annealing or for labeling may be achieved using an excess of the enzyme. If kinasing is for the labeling of probe, the ATP may contain high specific activity radioisotopes. Then, the DNA oligomer may be subjected to annealing and ligation with T4 ligase or the like.

10 B. A substantially pure EBI 1, EBI 2, and EBI 3 polypeptides.

15 In another embodiment, the present invention relates to a substantially pure polypeptide having an amino acid sequence corresponding to a polypeptide selected from the group consisting of EBI 1, EBI 2, and EBI 3 polypeptides, or at least 7 contiguous amino acids thereof (preferably, at least 10, 15, 20, or 30 contiguous amino acids thereof). In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof, or at least 7 contiguous amino acids thereof (preferably, at least 10, 15, 20, or 30 contiguous amino acids thereof).

20 A variety of methodologies known in the art can be utilized to obtain the peptide of the present invention. In one embodiment, the peptide is purified from tissues or cells which naturally produce the peptide. The samples of the present invention include cells, protein extracts or membrane extracts of cells, or biological fluids. The sample will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts used as the sample.

25 Any eukaryotic organism can be used as a source for the peptide of the invention, as long as the source organism naturally contains such a peptide.

As used herein, "source organism" refers to the original organism from which the amino acid sequence of the subunit is derived, regardless of the organism the subunit is expressed in and ultimately isolated from.

5 One skilled in the art can readily follow known methods for isolating proteins in order to obtain the peptide free of natural contaminants. These include, but are not limited to: immunochromatography, size-exclusion chromatography, HPLC, ion-exchange chromatography, and immuno-affinity chromatography.

C. A nucleic acid probe for the detection of Epstein Barr virus.

10 In another embodiment, the present invention relates to a nucleic acid probe for the detection of the presence of Epstein Barr Virus in a sample comprising the above-described DNA segments or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 40, or 50 thereof). In another preferred embodiment, the DNA segment has a nucleic acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:1, SEQ ID  
15 NO:3, and SEQ ID NO:5, or at least 20 contiguous nucleotides thereof (preferably at least 25, 30, 40, or 50 thereof). In another preferred embodiment, the nucleic acid probe encodes an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID  
20 NO:4, and SEQ ID NO:6, or at least 7 contiguous amino acids thereof.

The nucleic acid probe may be used to probe an appropriate chromosomal or cDNA library by usual hybridization methods to obtain another DNA segment of the present invention. A chromosomal DNA or cDNA library may be prepared from appropriate cells according to recognized  
25 methods in the art (cf. *Molecular Cloning: A Laboratory Manual, second edition*, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989).

In the alternative, chemical synthesis is carried out in order to obtain nucleic acid probes having nucleotide sequences which correspond to N-

terminal and C-terminal portions of the amino acid sequence of the polypeptide of interest. Thus, the synthesized nucleic acid probes may be used as primers in a polymerase chain reaction (PCR) carried out in accordance with recognized PCR techniques, essentially according to *PCR Protocols, A Guide to Methods and Applications*, edited by Michael *et al.*, Academic Press, 1990, utilizing the appropriate chromosomal or cDNA library to obtain the fragment of the present invention.

One skilled in the art can readily design such probes based on the sequence disclosed herein using methods of computer alignment and sequence analysis known in the art (cf. *Molecular Cloning: A Laboratory Manual, second edition*, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989).

The hybridization probes of the present invention can be labeled by standard labeling techniques such as with a radiolabel, enzyme label, fluorescent label, biotin-avidin label, chemiluminescence, and the like. After hybridization, the probes may be visualized using known methods.

The nucleic acid probes of the present invention include RNA, as well as DNA probes, such probes being generated using techniques known in the art.

In one embodiment of the above described method, a nucleic acid probe is immobilized on a solid support. Examples of such solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling nucleic acid probes to such solid supports are well known in the art.

The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The sample used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid

extracts of cells are well known in the art and can be readily adapted in order to obtain a sample which is compatible with the method utilized.

D. A method of detecting the presence of Epstein Barr virus in a sample.

5 In another embodiment, the present invention relates to a method of detecting the presence of Epstein Barr virus in a sample comprising a) contacting said sample with the above-described nucleic acid probe, under conditions such that hybridization occurs, and b) detecting the presence of said probe bound to said DNA segment. One skilled in the art would select the nucleic acid probe according to techniques known in the art as described  
10 above. Samples to be tested include but should not be limited to RNA samples of human tissue. The presence of EBI 1, EBI 2, or EBI 3 may represent that the cells had been infected with the Epstein Barr virus. Increases in the amount of EBI 1, EBI 2, or EBI 3 RNA in a sample may also indicate the presence of or infection with the Epstein Barr virus.

15 E. A kit for detecting the presence of Epstein Barr virus in a sample.

In another embodiment, the present invention relates to a kit for detecting the presence of Epstein Barr virus in a sample comprising at least one container means having disposed therein the above-described nucleic acid probe. In a preferred embodiment, the kit further comprises other containers  
20 comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound nucleic acid probe. Examples of detection reagents include, but are not limited to radiolabelled probes, enzymatic labeled probes (horse radish peroxidase, alkaline phosphatase), and affinity labeled probes (biotin, avidin, or streptavidin).

25 In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers

allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the probe or primers used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and the like), and containers which contain the reagents used to detect the hybridized probe, bound antibody, amplified product, or the like.

One skilled in the art will readily recognize that the nucleic acid probes described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.

F. DNA constructs comprising the EBI 1, EBI 2, or EBI 3 DNA segments and cells containing these constructs.

In another embodiment, the present invention relates to a recombinant DNA molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the above-described DNA segments.

In another embodiment, the present invention relates to a recombinant DNA molecule comprising a vector and an above-described DNA segment.

In another embodiment, the present invention relates to a DNA molecule comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding an amino acid sequence corresponding to the above-described polypeptide, and a transcriptional termination region functional in said cell.

Preferably, the above-described molecules are isolated and/or purified DNA molecules.

In another embodiment, the present invention relates to a cell that contains an above-described DNA molecule.



In another embodiment, the peptide is purified from cells which have been altered to express the peptide.

As used herein, a cell is said to be "altered to express a desired peptide" when the cell, through genetic manipulation, is made to produce a protein which it normally does not produce or which the cell normally produces at low levels. One skilled in the art can readily adapt procedures for introducing and expressing either genomic, cDNA, or synthetic sequences into either eukaryotic or prokaryotic cells.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene sequence expression. The precise nature of the regulatory regions needed for gene sequence expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the sequence encoding an EBI 1, EBI 2, or EBI 3 gene may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3'-region naturally contiguous to the DNA sequence encoding an EBI 1, EBI 2, or EBI 3 gene, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

Two DNA sequences (such as a promoter region sequence and an EBI 1, EBI 2, or EBI 3 sequence) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of an EBI 1, EBI 2, EBI 3 gene sequence, or (3) interfere with the ability of the an EBI 1, EBI 2, or EBI 3 gene sequence to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.

Thus, to express an EBI 1, EBI 2, or EBI 3 gene, transcriptional and translational signals recognized by an appropriate host are necessary.

The present invention encompasses the expression of the EBI 1, EBI 2, or EBI 3 gene (or a functional derivative thereof) in either prokaryotic or eukaryotic cells. Prokaryotic hosts are, generally, the most efficient and convenient for the production of recombinant proteins and, therefore, are preferred for the expression of the EBI 1, EBI 2, or EBI 3 gene.

Prokaryotes most frequently are represented by various strains of *E. coli*. However, other microbial strains may also be used, including other bacterial strains.

In prokaryotic systems, plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host may be used. Examples of suitable plasmid vectors may include pBR322, pUC18, pUC19 and the like; suitable phage or bacteriophage vectors may include  $\lambda$ gt10,  $\lambda$ gt11 and the like; and suitable virus vectors may include pMAM-neo, pKRC and the like. Preferably, the selected vector of the present invention has the capacity to replicate in the selected host cell.

Recognized prokaryotic hosts include bacteria such as *E. coli*, *Bacillus*, *Streptomyces*, *Pseudomonas*, *Salmonella*, *Serratia*, and the like. However, under such conditions, the peptide will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

To express EBI 1, 2, or 3 (or a functional derivative thereof) in a prokaryotic cell, it is necessary to operably link the EBI 1, EBI 2, or EBI 3 sequence to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible).  
5 Examples of constitutive promoters include the *int* promoter of bacteriophage  $\lambda$ , the *bla* promoter of the  $\beta$ -lactamase gene sequence of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, and the like. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage  $\lambda$  ( $P_L$  and  $P_R$ ), the *trp*,  
10 *recA*, *lacZ*, *lacI*, and *gal* promoters of *E. coli*, the  $\alpha$ -amylase (Ulmanen *et al.*, *J. Bacteriol.* 162:176-182 (1985)) and the  $\zeta$ -28-specific promoters of *B. subtilis* (Gilman *et al.*, *Gene sequence* 32:11-20 (1984)), the promoters of the bacteriophages of *Bacillus* (Gryczan, In: *The Molecular Biology of the Bacilli*, Academic Press, Inc., NY (1982)), and *Streptomyces* promoters (Ward *et al.*,  
15 *Mol. Gen. Genet.* 203:468-478 (1986)).

Prokaryotic promoters are reviewed by Glick (*J. Ind. Microbiol.* 1:277-282 (1987)); Cenatiempo (*Biochimie* 68:505-516 (1986)); and Gottesman (*Ann. Rev. Genet.* 18:415-442 (1984)).

Proper expression in a prokaryotic cell also requires the presence of a ribosome binding site upstream of the gene sequence-encoding sequence. Such  
20 ribosome binding sites are disclosed, for example, by Gold *et al.* (*Ann. Rev. Microbiol.* 35:365-404 (1981)).

The selection of control sequences, expression vectors, transformation methods, and the like, are dependent on the type of host cell used to express the gene. As used herein, "cell", "cell line", and "cell culture" may be used  
25 interchangeably and all such designations include progeny. Thus, the words "transformants" or "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA  
30 content, due to deliberate or inadvertent mutations. However, as defined,

mutant progeny have the same functionality as that of the originally transformed cell.

Host cells which may be used in the expression systems of the present invention are not strictly limited, provided that they are suitable for use in the expression of the EBI 1, 2, or 3 peptide of interest. Suitable hosts may often include eukaryotic cells.

Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, mammalian cells either *in vivo*, or in tissue culture. Mammalian cells which may be useful as hosts include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin, such as the hybridoma SP2/O-AG14 or the myeloma P3x63Sg8, and their derivatives. Preferred mammalian host cells include SP2/O and J558L, as well as neuroblastoma cell lines such as IMR 332 that may provide better capacities for correct post-translational processing.

In addition, plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences.

Another preferred host is an insect cell, for example the *Drosophila* larvae. Using insect cells as hosts, the *Drosophila* alcohol dehydrogenase promoter can be used. Rubin, *Science* 240:1453-1459 (1988). Alternatively, baculovirus vectors can be engineered to express large amounts of EBI 1, EBI 2, or EBI 3 in insects cells (Jasny, *Science* 238:1653 (1987); Miller *et al.*, In: *Genetic Engineering* (1986), Setlow, J.K., *et al.*, eds., *Plenum*, Vol. 8, pp. 277-297).

Any of a series of yeast gene sequence expression systems can be utilized which incorporate promoter and termination elements from the actively expressed gene sequences coding for glycolytic enzymes are produced in large quantities when yeast are grown in mediums rich in glucose. Known glycolytic gene sequences can also provide very efficient transcriptional control signals.

Yeast provides substantial advantages in that it can also carry out post-translational peptide modifications. A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number of plasmids which can be utilized for production of the desired proteins in yeast. Yeast recognizes leader sequences on cloned mammalian gene sequence products and secretes peptides bearing leader sequences (i.e., pre-peptides). For a mammalian host, several possible vector systems are available for the expression of EBI 1, EBI 2, or EBI 3.

A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, and the like, may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation.

As discussed above, expression of EBI 1, EBI 2, or EBI 3 in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer *et al.*, *J. Mol. Appl. Gen.* 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, *Cell* 31:355-365 (1982)); the SV40 early promoter (Benoist *et al.*, *Nature (London)* 290:304-310 (1981)); the yeast *gal4* gene sequence promoter (Johnston *et al.*, *Proc. Natl. Acad. Sci. (USA)* 79:6971-6975 (1982); Silver *et al.*, *Proc. Natl. Acad. Sci. (USA)* 81:5951-5955 (1984)).

As is widely known, translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes EBI 1, EBI 2, or EBI 3 (or a functional derivative thereof) does not contain any intervening codons which are capable of encoding a methionine (i.e., AUG). The presence of such codons results either in a formation of a fusion protein (if the AUG codon is in the same reading frame as the EBI 1, EBI 2, or EBI 3 coding sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the EBI 1, EBI 2, or EBI 3 coding sequence).

An EBI 1, EBI 2, or EBI 3 DNA segment and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as a non-replicating DNA (or RNA) molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the gene may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced DNA sequence into the host chromosome.

In one embodiment, a vector is employed which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression

vectors incorporating such elements include those described by Okayama, *Molec. Cell. Biol.* 3:280 (1983).

In a preferred embodiment, the introduced sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species. Preferred prokaryotic vectors include plasmids such as those capable of replication in *E. coli* (such as, for example, pBR322, ColE1, pSC101, pACYC 184,  $\pi$ VX. Such plasmids are, for example, disclosed by Sambrook (cf. *Molecular Cloning: A Laboratory Manual*, second edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989)). *Bacillus* plasmids include pC194, pC221, pT127, and the like. Such plasmids are disclosed by Gryczan (In: *The Molecular Biology of the Bacilli*, Academic Press, NY (1982), pp. 307-329). Suitable *Streptomyces* plasmids include pIJ101 (Kendall *et al.*, *J. Bacteriol.* 169:4177-4183 (1987)), and streptomyces bacteriophages such as  $\phi$ C31 (Chater *et al.*, In: *Sixth International Symposium on Actinomycetales Biology*, Akademiai Kaido, Budapest, Hungary (1986), pp. 45-54). *Pseudomonas* plasmids are reviewed by John *et al.* (*Rev. Infect. Dis.* 8:693-704 (1986)), and Izaki (*Jpn. J. Bacteriol.* 33:729-742 (1978)).

Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40, 2-micron circle, and the like, or their derivatives. Such plasmids are well known in the art (Botstein *et al.*, *Miami Wnter. Symp.* 19:265-274 (1982); Broach, In: *The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 445-470 (1981); Broach, *Cell* 28:203-204 (1982); Bollon *et al.*, *J. Clin. Hematol. Oncol.* 10:39-48 (1980); Maniatis, In: *Cell Biology: A*

*Comprehensive Treatise*, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608 (1980)).

5 Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means, i.e., transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, and the like. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the  
10 cloned gene sequence(s) results in the production of EBI 1, EBI 2, or EBI 3, or fragments thereof. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like).

15 A variety of incubation conditions can be used to form the peptide of the present invention. The most preferred conditions are those which mimic physiological conditions.

G. An antibody having binding affinity to an EBI 1, EBI 2, and EBI 3 polypeptide, or a binding fragment thereof and a hybridoma containing the antibody.

20 In another embodiment, the present invention relates to an antibody having binding affinity to a polypeptide having an amino acid sequence selected from the group consisting of EBI 1, EBI 2, and EBI 3 polypeptides, or a binding fragment thereof. In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group of sequences set forth in  
25 SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof, or at least 7 contiguous amino acids thereof (preferably, at least 10, 15, 20, or 30 contiguous amino acids thereof). In another preferred embodiment, the antibody is a monoclonal antibody.



In another embodiment, the present invention relates to a hybridoma which produces the above-described monoclonal antibody, or binding fragment thereof.

5       The EBI 1, EBI 2, or EBI 3 proteins of the present invention can be used in a variety of procedures and methods, such as for the generation of antibodies, for use in identifying pharmaceutical compositions, and for studying DNA/protein interaction.

10       The EBI 1, EBI 2, or EBI 3 peptide of the present invention can be used to produce antibodies or hybridomas. One skilled in the art will recognize that if an antibody is desired, such a peptide would be generated as described herein and used as an immunogen.

15       The antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies, and humanized forms. Humanized forms of the antibodies of the present invention may be generated using one of the procedures known in the art such as chimerization or CDR grafting.

20       The invention also provides hybridomas which are capable of producing the above-described antibodies. A hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody.

25       In general, techniques for preparing monoclonal antibodies and hybridomas are well known in the art (Campbell, *"Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology,"* Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth *et al.*, *J. Immunol. Methods* 35:1-21 (1980)).

30       Any animal (mouse, rabbit, and the like) which is known to produce antibodies can be immunized with the selected polypeptide. Methods for immunization are well known in the art. Such methods include subcutaneous or interperitoneal injection of the polypeptide. One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal which is immunized, the antigenicity of the polypeptide and the site of injection.

The polypeptide may be modified or administered in an adjuvant in order to increase the peptide antigenicity. Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or  $\beta$ -galactosidase) or through the inclusion of an adjuvant during immunization.

For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/O-Ag14 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells.

Any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz *et al.*, *Exp. Cell Res.* 175:109-124 (1988)).

Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, *Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, supra* (1984)).

For polyclonal antibodies, antibody containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures.

In another embodiment of the present invention, the above-described antibodies are detectably labeled. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, and the like), enzymatic labels (such as horse radish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, see (Sternberger *et al.*, *J. Histochem. Cytochem.* 18:315 (1970); Bayer *et al.*, *Meth. Enzym.* 62:308 (1979); Engval *et al.*, *Immunol.* 109:129 (1972); Goding, *J. Immunol. Meth.* 13:215 (1976)).

The labeled antibodies of the present invention can be used for *in vitro*, in

*vivo*, and *in situ* assays to identify cells or tissues which express a specific peptide.

In another embodiment of the present invention the above-described antibodies are immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir *et al.*, "*Handbook of Experimental Immunology*" 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby *et al.*, *Meth. Enzym.* 34 Academic Press, N.Y. (1974)). The immobilized antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays as well as in immunochromotography.

Furthermore, one skilled in the art can readily adapt currently available procedures, as well as the techniques, methods and kits disclosed above with regard to antibodies, to generate peptides capable of binding to a specific peptide sequence in order to generate rationally designed antipeptide peptides, for example see Hurby *et al.*, "Application of Synthetic Peptides: Antisense Peptides", In *Synthetic Peptides, A User's Guide*, W.H. Freeman, NY, pp. 289-307 (1992), and Kaspczak *et al.*, *Biochemistry* 28:9230-8 (1989).

Anti-peptide peptides can be generated in one of two fashions. First, the anti-peptide peptides can be generated by replacing the basic amino acid residues found in the EBI 1, EBI 2, or EBI 3 peptide sequence with acidic residues, while maintaining hydrophobic and uncharged polar groups. For example, lysine, arginine, and/or histidine residues are replaced with aspartic acid or glutamic acid and glutamic acid residues are replaced by lysine, arginine or histidine.

#### H. A method of detecting an EBI 1, EBI 2, or EBI 3 polypeptide in a sample.

In another embodiment, the present invention relates to a method of detecting a polypeptide selected from the group consisting of EBI 1, EBI 2,

EBI 3 in a sample, comprising: a) contacting the sample with an above-described antibody, under conditions such that immunocomplexes form, and b) detecting the presence of said antibody bound to the polypeptide. In detail, the methods comprise incubating a test sample with one or more of the antibodies of the present invention and assaying whether the antibody binds to the test sample. The presence of an EBI 1, EBI 2, or EBI 3 polypeptide or fragment thereof in a sample may indicate the presence or infection of Epstein Barr virus.

Conditions for incubating an antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the antibody used in the assay. One skilled in the art will recognize that any one of the commonly available immunological assay formats (such as radioimmunoassays, enzyme-linked immunosorbent assays, diffusion based Ouchterlony, or rocket immunofluorescent assays) can readily be adapted to employ the antibodies of the present invention. Examples of such assays can be found in Chard, "An Introduction to Radioimmunoassay and Related Techniques" Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock *et al.*, "Techniques in Immunocytochemistry," Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, "Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology," Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The immunological assay test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is capable with the system utilized.

I. A diagnostic kit comprising antibodies to EBI 1, EBI 2, and EBI 3.

In another embodiment of the present invention, a kit is provided which contains all the necessary reagents to carry out the previously described methods of detection. The kit may comprise: i) a first container means  
5 containing an above-described antibody, and ii) second container means containing a conjugate comprising a binding partner of the antibody and a label. In another preferred embodiment, the kit further comprises one or more other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound antibodies. Examples of  
10 detection reagents include, but are not limited to, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the chromophoric, enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. The compartmentalized kit may be as described above for nucleic acid probe kits.

15 One skilled in the art will readily recognize that the antibodies described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.

The present invention is described in further detail in the following non-limiting examples.

20 **EXAMPLES**

The following protocols and experimental details are referenced in the examples that follow:

Cells and cell lines. BL41 and BL30 are EBV(-) Burkitt lymphoma cell lines. The BL41/B95-8 and BL41/P3HR1 cell lines were derived by  
25 infecting BL41 with the transforming EBV strain, B95-8, or with the non-transforming strain, P3HR1, respectively (Favrot, M.C., *et al.*, *Intl. J. Cancer* 38(6):901-6 (1986)). IB4 is a latently infected B lymphoblastoid cell line established by infection of B lymphocytes with EBV (B95-8) *in vitro*.

RHEK-1 (generous gift from Dr. Jong Rhim, National Cancer Institute, Bethesda, MA) is a human keratinocyte line derived by infection of primary foreskin epithelial cells with an adenovirus 12/SV40 hybrid-virus. K562 is a Philadelphia chromosome-positive human chronic myeloid leukemia cell line. U937 is a histiocytic lymphoma cell line with monocytic features. HL60 is a promyelocytic leukemia line. HSB-2 and Jurkat are human T lymphoblastic leukemia cell lines. TK143 was derived from a human osteosarcoma.

Human mononuclear cells (PBMC) were purified from peripheral blood by centrifugation on a ficoll cushion (Ficoll-Hypaque, Pharmacia, Vineland, NJ). Cells were resuspended at  $1 \times 10^6$  cells/ml in RPMI medium supplemented with 20% fetal bovine serum, and were divided into parallel cultures grown 72 h with or without  $2.5 \mu\text{g/ml}$  pokeweed mitogen (PWM, Sigma, St. Louis, MO). T cells were isolated from purified PBMCs by rosetting overnight with aminoethylisothiuronium bromide (AET) treated sheep erythrocytes at  $4^\circ\text{C}$ , followed by centrifugation over ficoll. Pelleted erythrocytes were lysed with ammonium chloride. The remaining T cells were resuspended in RPMI with 20% fetal bovine serum at  $1 \times 10^6$  cells/ml. Phytohemagglutinin (PHA, Sigma) was added to a final concentration of  $1.0 \mu\text{g/ml}$ . Cells were cultured for 72 h and harvested for extraction of total cellular RNA.

**RNA preparation and analysis.** Cytoplasmic RNA was isolated from exponentially growing cells by a modification of the acid phenol/guanidinium isothiocyanate extraction procedure, followed by reprecipitation in guanidinium hydrochloride/ethanol. Total cellular RNA was extracted from 0.2 to 2 g samples of human spleen and tonsil obtained from surgical specimens, and from human postmortem bone marrow. Tissues were homogenized in acid phenol/guanidinium isothiocyanate using a rotary tissue homogenizer, extracted and precipitated. After dissolution in guanidinium hydrochloride and reprecipitation with ethanol, human tissue RNA samples were resuspended in  $\text{H}_2\text{O}$  and precipitated by addition of an equal volume of 8 M LiCl. The polyadenylated fractions of BL41 or BL41/B95-8 RNA were purified by

2 successive cycles of chromatography on oligodeoxythymidylate cellulose. Polyadenylated IB4 RNA was purified by a single round of oligodeoxythymidylate selection. RNA samples (12  $\mu$ g per lane) were size fractionated on 0.66 M formaldehyde, 1% agarose gels and transferred to charged nylon membranes (GeneScreen Plus, New England Nuclear, Billerica, MA) for subsequent hybridization analysis. To examine gene expression in other human tissues, a commercially prepared blot was purchased containing 2  $\mu$ g of polyadenylated heart, brain, placenta, lung, liver, kidney, skeletal muscle and pancreas RNA (Multiple Tissue Northern, Clontech, Palo Alto, CA).

Probes were prepared from cloned cDNA inserts using random hexamer primers and  $^{32}$ P-dCTP. The beta actin probe was generated using a previously described 1.4 kb cDNA (Alfieri, C., *et al.*, *Virology* 181(2):595-608 (1991)). The glyceraldehyde phosphate dehydrogenase (GAPDH) probe was prepared from a commercially obtained DNA fragment (Clontech). Filters were hybridized for 18 to 24 h at 47°C in a hybridization buffer consisting of 50% formamide, 6X SSPE (20X SSPE: 3.0 M NaCl, 200 mM NaPO<sub>4</sub>, pH7.4, 20 mM EDTA), 1% SDS, 1X Denhardt's solution (100X Denhardt's: 2% BSA, 2% polyvinylpyrrolidone, 2% Ficoll), and 100  $\mu$ g/ml sheared single-stranded herring testis DNA. Filters were washed according to the manufacturers' instructions, with high stringency washes performed at 67°-70°C in 1% SDS, 0.2X SSC, and exposed to preflashed film (X-OMAT AR, Kodak, Rochester, NY) at -80°C for 2 h to 10 days. Autoradiographic signal intensities were quantitated by densitometric scanning using a Beckman DU-8 spectrophotometer equipped with a slab gel Compuset Module. Induction factors were calculated for each probe as signal intensity ratios for EBV(+) versus EBV(-) cells, divided by the ratio of beta actin signal intensities.

*cDNA library preparation.* First strand cDNA was prepared from 5  $\mu$ g polyadenylated BL41/B95-8 RNA using Moloney murine leukemia virus reverse transcriptase (SuperScript, Bethesda Research Laboratories,

Gaithersburg, MD) and oligodeoxthymidylate primers in a 100  $\mu$ L reaction. Second strand cDNA was synthesized using *E. coli* DNA polymerase I and RNase H. The double stranded cDNA was blunt-ended with T4 DNA polymerase and EcoRI methylated. After ligation of EcoRI linkers, the cDNA was EcoRI restriction digested and size fractionated by gel filtration chromatography on Sepharose CL-4B. The purified cDNA was ligated to phosphorylated lambda gt10 arms (Promega, Madison, WI) and packaged (Gigapack Gold, Stratagene, La Jolla, CA).

*Subtractive probe preparation.* Radiolabelled cDNA was prepared from 6  $\mu$ g of polyadenylylated BL41 or BL41/B95-8 RNA in a 200  $\mu$ L reaction containing 50  $\mu$ g/ml random DNA hexamers; 0.5 mM dATP, dGTP, dTTP; 25  $\mu$ M unlabelled dCTP; 1.0 mCi  $^{32}$ P-dCTP (800 Ci/mMole, New England Nuclear); 2000 units recombinant Moloney murine leukemia virus reverse transcriptase. Reactions were 42°C for 1 h. After precipitation, reaction products were resuspended in 0.1 M NaOH and incubated 20 min. at 65°C to hydrolyze RNA templates. Probes were neutralized with 0.1 M acetic acid and size fractionated on G-50 Sephadex. Biotinylated RNA was prepared from polyadenylylated BL41 RNA using a photoactivatable azido-aryl biotin reagent (Photoprobe Biotin, Vector Laboratories, Burlingame, CA) following the manufacturer's protocol. Probe fractions were combined with 48  $\mu$ g (for BL41/B95-8 probe) or 12  $\mu$ g (for BL41 probe) biotinylated BL41 RNA and precipitated with ethanol. BL41/B95-8 probes were hybridized with an 8 fold excess (2 mg/ml) of biotinylated BL41 RNA; while BL41 control probes were hybridized with a 2 fold excess (0.5  $\mu$ g/ml) of biotinylated BL41 RNA. Hybridizations and subtractions were performed using the "Subtractor" kit (Invitrogen, San Diego, CA) according to the manufacturer's instructions. The precipitated cDNA/RNA mixtures were resuspended in 10 to 20  $\mu$ L H<sub>2</sub>O and heated to 100°C for 1 min. An equal volume of 2X hybridization buffer (Invitrogen) was added and the mixture was incubated at 65°C for 20 to 24 h. Following addition of an equal volume of HEPES buffer (10 mM HEPES, pH 7.5, 1 mM EDTA), 20  $\mu$ g streptavidin was added and the mixture was



incubated on ice for 10 min. Biotinylated RNA and RNA:cDNA duplexes, complexed with avidin, were removed by repeated phenol/chloroform extractions. The single stranded, subtracted BL41 cDNA probe which remained in the aqueous phase was used directly for *in situ* filter hybridizations. Aqueous phase BL41/B95-8 cDNA probe was precipitated with ethanol and subjected to a second round of subtraction under identical conditions prior to use in filter hybridizations. Duplicate filters were made from 145 mm plates containing 6000 recombinant bacteriophage and were hybridized in parallel to equal amounts of BL41/B95-8 or BL41 subtracted probes. Filters were hybridized at 48°C for 48 to 72 h in a buffer consisting of 50% formamide, 6X SSPE, 1% SDS, 10% dextran sulfate, 2X Denhardt's solution, 100 µg/ml sheared single-stranded herring testis DNA, and 10 µg/ml poly rA:rU (Sigma, St. Louis, MO). Filters were washed at 72°C in 0.2X SSC and exposed 3 to 7 days to preflashed film (Kodak X-OMAT AR). Differentially expressed genes were identified by overlaying films from corresponding filters. Clones selected on primary screening were rescreened once at low density to verify differential expression and for plaque purification.

**Analysis of clones.** DNA was extracted from bulk liquid cultures of purified lambda gt10 clones and digested with EcoRI. cDNA inserts were purified by agarose gel electrophoresis and subcloned into pBluescript (+). Nucleotide sequences were determined and were compared by the BLAST algorithm (Altschul, S.F., *et al.*, *J. Mol. Biol.* 215(3):403-10 (1990)) with known sequences resident in the National Center for Biotechnology Information databases using the Experimental GENINFO® BLAST Network Service, accessed through the Molecular Biology Computer Research Resource of the Dana-Farber Cancer Institute. Multiple sequence alignments were performed by the method of Higgins and Sharp (Higgins and Sharp, *Gene* 73(1):237-44 (1988)) using the CLUSTAL program (PCGene, IntelliGenetics, Mountain View, CA) with open gap and unit gap costs of 10.

**EXAMPLE 1*****Identification of cDNA Clones  
of EBV Induced RNAs by Subtracted Probe Hybridization***

5 CDNA clones of RNA from an *in vitro* EBV-infected BL cell line, BL41/B95-8 [EBV(+) BL41], were differentially screened with an EBV(+) BL41 cDNA probe from which sequences complementary to EBV(-) BL41 cell RNA had been specifically removed, and with an EBV(-) BL41 control cDNA probe. Sequences complimentary to EBV(-) BL41 RNA were removed from the EBV(+) BL41 RNA cDNA probes by two subtractions with an 8 fold  
10 excess of biotinylated EBV(-) BL41 RNA. Overall, 85-95% of the labeled EBV(+) BL41 probe was removed by the two subtractions. EBV(-) BL41 cDNA control probe was subtracted only once, removing 60-85% of the probe; thereby reducing hybridization to plaques containing cDNAs from abundant RNAs so that hybridization to cDNAs from less abundant BL41  
15 RNAs was evident.

Seventy-five phage cDNA clones differentially hybridized to the EBV(+) BL41 probe on the first screen of 75,000 recombinant phage. Twenty-five clones were consistently positive on rescreening. The eighteen clones which demonstrated the greatest reactivity with the EBV(+) versus the  
20 EBV(-) BL41 cDNA probes were selected for nucleotide sequencing and RNA blot hybridization.

**EXAMPLE 2*****Nucleotide Sequences of EBV Induced cDNAs***

The first 12 clones are described in Table 1. Ten clones matched 7  
25 previously characterized genes: two independent clones each of the complement receptor type 2 (CD21), the serglycin proteoglycan core protein and vimentin; and one clone each of cathepsin H, annexin VI (p68), the myristylated alanine-rich protein kinase C substrate (MARCKS) and the

lymphocyte hyaluronic acid receptor (CD44). The 2.6 kb MARCKS cDNA precisely matched the previous 1.58 kb human MARCKS cDNA clone (Harlan, D.M., *et al.*, *J. Biol. Chem.* 266(22):14399-405 (1991)) at its 5 prime end. The 3 prime untranslated region of the new clone is highly homologous to bovine MARCKS cDNA (Stumpo, D.J., *et al.*, *Proc. Natl. Acad. Sci. USA* 86(11):4012-6 (1989)).

The two remaining clones are from novel RNAs, EBV induced genes 1 (EBI 1) and 2 (EBI 2), whose nucleotide sequences can be predicted to encode G-protein coupled peptide receptors. The complete nucleotide and deduced amino acid sequences of the EBI 1 and EBI 2 cDNAs are shown in Figures 1A and 1B, respectively. Because the first EBI 1 cDNA was 1.2 kb, significantly shorter than the 2.4 kb RNA, 20 other cDNA clones were obtained using the initial cDNA as a probe. The largest clone is 2153 nucleotides (nt) and has a 1134 nt open-reading frame (Figure 1A). This clone is probably nearly full length, since it is close to the expected size, considering it has only a short poly A tail. Translation is likely to initiate from either of two AUGs, at nt 64-66 or 82-84, the first of which conforms to a consensus translational initiation sequence (Kozak, M., *J. Biol. Chem.* 266(30):19867-70 (1991)). An in-frame stop codon at nt 10-12 is consistent with downstream initiation at nt 64-66. The polypeptide encoded by the sequence beginning at nt 64 has a predicted molecular weight of 42.7 kD and includes eight hydrophobic domains likely to mediate membrane insertion. The first hydrophobic domain begins at the amino terminus and ends at a predicted signal peptidase cleavage site. The 7 remaining hydrophobic domains are characteristic of the G-protein coupled receptor family. Potential asparagine linked glycosylation sites are present in the extracellular amino terminal segment and in the third extracellular loop.

Since the initial EBI 2 cDNA was 1643 nt and approximated the size expected from a 1.9kb polyadenylated RNA, further cDNA clones were not obtained. The EBI 2 cDNA contains a 1083 nt open reading frame with two methionine codons are at nt 34-36 and 46-48 (Figure 1B). Although neither

methionine codon is in a favored initiation context (Kozak, M., *J. Biol. Chem.* 266(30):19867-70 (1991)), an upstream, in-frame termination codon and the absence of other potential open reading frames is consistent with translation initiating at the first or second methionine codon. Initiation at the first would  
5 result in a 41.2 kD protein. The deduced amino acid sequence predicts 7 hydrophobic transmembrane segments in the characteristic configuration of G-protein coupled receptors. In contrast to the EBI 1 protein, EBI 2 lacks a signal peptide. A possible N-linked glycosylation site is found in the amino terminal extracellular domain. Though the EBI 2 cDNA lacks a polyadenylate  
10 tail, a canonical polyadenylation signal (AATAAA) near the 3 prime end is consistent with the cDNA being essentially complete.

### EXAMPLE 3

#### *Comparison of EBI 1 and 2 with other G protein coupled receptors*

The EBI 1 and EBI 2 nucleotide and predicted amino acid sequences  
15 were compared with the Genbank (release 72 and updates), EMBL (release 31), Genbank translation, Swiss protein (release 22) and Protein Identification Resource (PIR, release 33) databases, using the BLAST algorithm (Altschul, S.F., *et al.*, *J. Mol. Biol.* 215(3):403-10 (1990)). EBI 1 and EBI 2 are homologous to G protein associated receptors. EBI 1 is highly homologous  
20 to the human high or low affinity interleukin 8 (IL-8) receptors at both the nucleotide (data not shown) and amino acid sequence levels. IL8 receptor itself is not expressed on lymphocytes (Holmes, W.E., *et al.*, *Science* 253(5025):1278-80 (1991); Murphy and Tiffany, *et al.*, *Science* 253:1280-1283 (1991)). Excluding the putative EBI 1 signal peptide, the overall amino  
25 acid identity among the 3 proteins exceeds 30%, with conservative changes observed at many of the non-identical residues. The identity increases to 40% when EBI 1 is compared with either IL-8 receptor individually. Additional similarities with the IL-8 receptors include a high proportion of serine and threonine near the carboxy terminus, and a highly acidic amino terminal

extracellular domain. The IL-8 receptor acidic residues are implicated in binding IL-8 basic amino acids (Holmes, W.E., *et al.*, *Science* 253(5025):1278-80 (1991); Murphy and Tiffany, *et al.*, *Science* 253:1280-1283 (1991).

5           The EBI 2 gene does not have such a close homologue. EBI 2 has 24% amino acid identity to the thrombin receptor (Vu, T.K., *et al.*, *Cell* 64(6):1057-68 (1991)). Less extensive homologies are observed with a number of other G-protein coupled receptors, including the receptors for vasoactive intestinal polypeptide, somatostatin (type 1) and angiotensin II, as  
10       well as the low affinity IL-8 receptor. EBI 2 also exhibits more distant homologies with EBI 1 and the high affinity IL-8 receptor. Significantly, these are the same proteins which, in different order, exhibit the closest homologies with the EBI 1 protein. Together they constitute a subfamily of G-protein coupled peptide receptors. The greatest conservation of residues  
15       among these proteins extends from the first transmembrane domain to the second intracellular loop. Because of the particular conservation of an amino acid sequence among these G protein coupled receptors, we are able to identify a new highly conserved sequence motif at the carboxy end of TM III and the adjacent second intracellular loop. This motif, S-(I/L)-D-R-(Y/F)-X-  
20       X-X-X, with x being a hydrophobic amino acid, is in a wide variety of G-protein coupled receptors; and is not in other proteins in the data bases surveyed. Other highly conserved features of G protein coupled receptors in EBI 1 and 2 include the asparagine in TM I, the proline in TM II, the aspartate in the first intracellular loop, and the tryptophane and cysteine in the  
25       first extracellular loop. This cysteine has been postulated to be involved in disulfide linkage to a conserved cysteine present in the second extracellular loop in several other receptors, including the beta adrenergic and thrombin receptors.

**EXAMPLE 4***Analysis of induced gene expression by RNA blot hybridization*

Probes from seven of the nine EBV induced cDNAs were hybridized to identical blots of polyadenylated RNA from the EBV(+) or EBV(-) BL41 cell lines or from the EBV transformed lymphoblastoid cell line, IB4 (Figure 2). Vimentin and CD21 were previously shown to be EBV induced and were not further evaluated. The RNAs loaded in the EBV(+), BL41, and EBV(-) BL41 lanes were standardized with respect to beta actin reactivity. Significantly less IB4 cell RNA was used due to the high abundance of the putative induced gene RNAs in these cells (Figure 2, Actin probe). Probes from each of the cDNA clones detected RNAs which are significantly more abundant in both IB4 and EBV(+) BL41 cells than in EBV(-) BL41 cells. Induction factors indicated in Table 1 were determined by quantitative densitometric scanning of autoradiographs and reflect the fold enhancement of signal intensities in EBV(+) BL41 cells compared with EBV(-) BL41 cells, corrected for the ratio of actin reactivities. Standardization by actin reactivity, however, significantly underestimates the absolute induction levels since actin is induced 3-fold by EBV infection of BL41 cells relative to glyceraldehyde phosphate dehydrogenase, (GAPDH), or to total RNA amounts quantitated spectrophotometrically. To achieve equal actin signal intensities, 3-fold more EBV(-) BL41 than EBV(+) BL41 RNA was loaded per lane. Importantly, each of the RNAs was at least as abundant in IB4 cells relative to GAPDH as in EBV(+) BL41 (Figure 2).

EBI 1, EBI 2, CD44 and MARCKS are the most induced of the seven genes. The CD44 gene encodes three distinct RNAs of 1.6, 2.2 and 4.8 kb respectively in both IB4 and EBV(+) BL41 cells. No CD44 RNA was detected EBV(-) BL41 cells even after prolonged autoradiographic exposures. EBI 2 RNA was also undetectable in EBV(-) BL41 cells.

**EXAMPLE 5*****Expression of EBI 1 and 2 in human cell lines and tissues***

The expression of EBI 1 and 2 in human cell lines and tissues was evaluated by hybridizing actin, EBI 1 or EBI 2 probes to blots of cell line or tissue RNAs. While EBI 1 is weakly expressed in BL41, EBI 2 is not; and, neither EBI 1 nor EBI 2 are expressed in another EBV(-) BL cell line, BL30 (Figure 3). EBI 1 and EBI 2 RNAs are abundant in primary human lymphocytes transformed by EBV *in vitro* and propagated as continuous lymphoblastoid cell lines for several years (IB4) or for less than 1 year (W91-LCL) (Figure 3). EBI 1 RNA is faintly detectable in the human T cell line Jurkat, and is abundantly expressed in a second T cell line, HSB-2 (Figure 3). EBI 2 RNA is not detected in either T cell line (Figure 3), nor in a third T cell line, MOLT-4. EBI 1 is not expressed in the human promyelocytic line, HL60, the chronic myelogenous leukemia cell line K562, the epithelial cell line, RHEK-1, the fibroblast-like osteosarcoma cell line, TK143, or the monocytic cell line, U937 (Figure 3). EBI 2, however, is expressed weakly, relative to actin, in HL60, U937 (U937 RNA is partially degraded) or HeLa cells (Figure 3).

EBI 1 and 2 RNAs are abundant in human spleen, somewhat less abundant relative to actin in tonsil and are not detectable in bone marrow (Figure 3). Both genes were expressed in resting PBMCs at levels comparable to IB4 or LCL-W91 B lymphoblastoid cells (Figure 3). Expression increased in parallel cultures stimulated for 72 h with pokeweed mitogen (PWM), although actin expression also increased with PWM (Figure 3). The EBI 1 and 2 RNA in stimulated and non stimulated PBMC cultures is likely to be mostly in B lymphocytes since EBI 1 RNA is at low levels and EBI 2 RNA is absent from phytohemagglutinin stimulated, PBMC derived, T lymphocytes (Figure 3). These findings are consistent with expression patterns observed in T cell lines.

EBI 1 and 2 RNA levels were also evaluated in a variety of non-hematopoietic human tissues. The EBI 1 probe detects small amounts of RNA

in both lung and pancreas (Figure 4). Rehybridization of this blot with an immunoglobulin mu chain probe (Figure 4, Igu probe) indicated that these tissue preparations contained significant amounts of immunoglobulin RNA, probably due to B lymphocytes in the tissues. Since EBI 1 RNA is abundant in peripheral blood lymphocytes, the EBI 1 RNA in the lung and pancreas is likely to be due to B lymphocytes. Similarly, the low level of EBI 2 RNA detected in pancreatic tissue is probably due to infiltrating B lymphocytes (Figure 4). However, the abundance of EBI 2 RNA in the lung is too great to attribute to lymphocyte contamination and is more likely due to specific expression in pulmonary epithelial cells or macrophages (Figure 4).

#### EXAMPLE 6

##### *Cloning and Characterization of EBI 3*

Subtractive hybridization screening of a BL41/B95-8 cDNA library has permitted the identification of a number of genes expressed at higher levels in EVB-infected BL cells compared with matched EBV(-) cells. Twenty-five putative EBV-induced gene clones were initially isolated. Of these, 13 clones matched 8 previously known genes. The remaining 12 clones represented 10 novel genes. Two of these clones were derived from transcripts of a previously uncharacterized gene designated EBV-induced gene 3 (EBI 3).

The complete nucleotide and amino acid sequence of the larger EBI 3 clone are shown in Figure 5 (SEQ ID NO:5 and SEQ ID NO:6, respectively). The 1182 nucleotide cDNA contains a 690 nucleotide open reading frame. A unique AUG codon preceding this reading frame at nucleotides 14-16 conforms to the Kozak consensus translational initiation sequence. Initiation from this site results in the synthesis of a polypeptide with a predicted molecular mass of 25,380 Daltons. The first 20 amino acids are highly hydrophobic and likely form a signal peptide for membrane translocation with a predicted signal peptidase cleavage site following a glycine residue at position 20. Two potential asparagine-linked glycosylation sites are also



identified. However, no other hydrophobic segments capable of forming the transmembrane domain of an integral membrane protein are evident. To verify the structure of this cDNA, five additional clones were retrieved from the library. All of these exhibited identical sequences throughout the putative carboxy-terminal portion of the predicted protein. The 3' end of the EBI 3 nucleotide sequence is notable for its homology to the left monomer of the human Alu repeat element. This homology extends to and includes the A-rich sequences which immediately precede the polyadenylate tail of the mRNA.

The EBI 3 nucleotide and amino acid sequences were compared with all known sequences of Genbank nucleic acid, and Genbank translation, Protein Identification Resource (PIR) and Swiss Protein databases, respectively, using the Experimental GENINFO(R) BLAST-server network of the National Center for Biotechnology Information. No significant nucleotide homologies were observed, excluding matches with the 3' untranslated Alu repeat. However, the predicted EBI 3 protein is approximately 30% identical to the receptor for ciliary neurotrophic factor (CNTF), with conservative amino acid changes at many of the non-identical residues. Of particular significance is the pattern of conserved residues which include 4 cysteines at positions 35, 46, 80 and 90 respectively of the complete EBI 3 protein sequence; tryptophanes at positions 48 and 150; proline at position 125; and aliphatic hydrophobic residues at positions 128, 136, 148 and 204. In addition, the EBI 3 sequence LSDWS at residues 215 to 219 closely matches the WSDWS sequence of the CNTF receptor. These conserved structural features are characteristic of and unique to members of the cytokine receptor family. The predicted EBI 3 protein exhibits less extensive homologies with the p40 subunit of interleukin 12 (IL-12), also known as natural killer cell stimulatory factor. Though a secreted protein, IL-12 p40 possesses the same conserved residues and is also a member of the cytokine receptor family. In addition, the carboxy terminal 100 amino acids of the EBI 3 protein exhibit structural homologies with type III fibronectin domains of a variety of adhesion related molecules, including tenascin, cytotactin and the neural cell

adhesion molecule, NCAM. This feature has also been described among other cytokine receptor family members.

Hybridization of a  $^{32}\text{P}$ -labeled EBI 3 probe to RNA blots detects a 1.5 kb RNA in the EBV-infected cell lines IB4 and BL41/B95-8 (Figure 6). EBI 3 RNA is undetectable, however, in the EVB(-) control cell line BL41. To provide standards for the amounts of RNA loaded in each line, parallel blots were hybridized with probes for glyceraldehyde phosphate dehydrogenase (GAPDH) and actin. These probes indicate that the BL41 lane contains as much or more RNA than the EBV-infected cell lanes.

Examination of a series of human cell lines and lymphoid tissues indicated that EBI 3 is expressed at very low levels in normal unfractionated resting lymphocytes of spleen and tonsil, but is undetectable in peripheral blood mononuclear cells (PBMC). However, stimulation of PBMC with the B and T lymphocyte activating agent, pokeweed mitogen, results in induction of the EBI 3 mRNA. Lower levels of EBI 3 RNA were detected in phytohemagglutinin stimulated peripheral blood T lymphocytes. In addition to IB4 and BL41/B95-8 cells, a recently established lymphoblastoid cell line transformed with the W91 EBV strain also exhibited significant EBI 3 expression. EBI 3 RNA was undetectable in a second EBV(-) BL cell line, BL30, in BL41 cells infected with the non-transforming P3HRI EBV strain, and in all human myeloid, T lymphoid or epithelial cell line examined.

Expression of EBI 3 RNA was also analyzed in a variety of non-lymphoid human tissues (Figure 7A). Abundant expression was observed in placenta, significantly exceeding expression levels observed in any lymphoid cell type. EBI 3 RNA was also faintly detectable in liver RNA. However, rehybridization of this blot with an immunoglobulin  $\mu$  heavy chain probe indicated detectable Ig gene expression, probably due to infiltration of liver tissue with lymphocytes *in vivo*. The apparent expression of EBI 3 in liver could therefore be due to expression in resident lymphocytes.

\* \* \* \* \*

All publications mentioned hereinabove are hereby incorporated in their entirety by reference.

5 While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.

Table 1				
Summary of EBV Induced RNA:cDNA Clones				
Clone	Gene	cDNA Size (kb)	RNA Size (kb)	Induction <sup>1</sup>
1.1	CD44	1.3	1.6, 2.2, 5.0	> 100X
3.3; 7.3	CD21	2.1; 1.8	4.8	
6.5	MARCKS	2.6	2.9	30X
8.2	Cathepsin H	1.5	1.7	6X
10.4; 11.4	Serglycin	1.1; 1.1	1.4	3.5X
12.3	Annexin VI	2.3	3.0	5X
12.5; 13.0	Vimentin	1.0; 1.8	2.0	
6.4	EBI 1	1.2 (2.14) <sup>2</sup>	2.4	21X
3.2	EBI 2	1.64	1.9	> 200X
	Beta actin		2.2	3X <sup>3</sup>
<sup>1</sup> Induction levels were calculated as ratio of signal intensities (BL41/B95-8 to BL41) for individual probes, divided by ratio of signal intensities for Actin probe. <sup>2</sup> The 1.2 kb EBI 1 clone identified on initial screen was incomplete. Rescreening of the cDNA library resulted in isolation of several additional full-length clones, the largest of which was 2.14 kb. <sup>3</sup> Induction of beta actin RNA was calculated as ratio of actin signal intensities, to ratio of signal intensities for glyceraldehyde phosphate dehydrogenase probe.				

-51-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Birkenbach, Mark  
Kieff, Elliot

(ii) TITLE OF INVENTION: Epstein Barr Virus Induced Genes

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Sterne, Kessler, Goldstein & Fox  
(B) STREET: 1100 New York Avenue N.W., Suite 600  
(C) CITY: Washington  
(D) STATE: D.C.  
(E) COUNTRY: U.S.A.  
(F) ZIP: 20005-3934

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT (to be assigned)  
(B) FILING DATE: herewith  
(C) CLASSIFICATION:

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (202) 371-2600  
(B) TELEFAX: (202) 371-2540

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2154 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: both  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 64..1197

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGAATTCCGT AGTGCGAGGC CGGGCACAGC CTCCTGTGT GGTTTTACCG CCCAGAGAGC	60
GTC ATG GAC CTG GGG AAA CCA ATG AAA AGC GTG CTG GTG GCT CTC	108
Met Asp Leu Gly Lys Pro Met Lys Ser Val Leu Val Val Ala Leu	
1 5 10 15	
CTT GTC ATT TTC CAG GTA TGC CTG TGT CAA GAT GAG GTC ACG GAC GAT	156
Leu Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp	
20 25 30	
TAC ATC GGA GAC AAC ACC ACA GTG GAC TAC ACT TTG TTC GAG TCT TTG	204
Tyr Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu	
35 40 45	
TGC TCC AAG AAG GAC GTG CGG AAC TTT AAA GCC TGG TTC CTC CCT ATC	252
Cys Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile	
50 55 60	
ATG TAC TCC ATC ATT TGT TTC GTG GGC CTA CTG GGC AAT GGG CTG GTC	300
Met Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val	
65 70 75	
GTG TTG ACC TAT ATC TAT TTC AAG AGG CTC AAG ACC ATG ACC GAT ACC	348
Val Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr	
80 85 90 95	
TAC CTG CTC AAC CTG GCG GTG GCA GAC ATC CTC TTC CTC CTG ACC CTT	396
Tyr Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu	
100 105 110	
CCC TTC TGG GCC TAC AGC GCG GCC AAG TCC TGG GTC TTC GGT GTC CAC	444
Pro Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His	
115 120 125	
TTT TGC AAG CTC ATC TTT GCC ATC TAC AAG ATG AGC TTC TTC AGT GGC	492
Phe Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly	
130 135 140	
ATG CTC CTA CTT CTT TGC ATC AGC ATT GAC CGC TAC GTG GCC ATC GTC	540
Met Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val	
145 150 155	
CAG GCT GTC TCA GCT CAC CGC CAC CGT GCC CGC GTC CTT CTC ATC AGC	588
Gln Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser	
160 165 170 175	
AAG CTG TCC TGT GTG GGC AGC GCC ATA CTA GCC ACA GTG CTC TCC ATC	636
Lys Leu Ser Cys Val Gly Ser Ala Ile Leu Ala Thr Val Leu Ser Ile	
180 185 190	

-53-

CCA GAG CTC CTG TAC AGT GAC CTC CAG AGG AGC AGC AGT GAG CAA GCG Pro Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala 195 200 205	684
ATG CGA TGC TCT CTC ATC ACA GAG CAT GTG GAG GCC TTT ATC ACC ATC Met Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile 210 215 220	732
CAG GTG GCC CAG ATG GTG ATC GGC TTT CTG GTC CCC CTG CTG GCC ATG Gln Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met 225 230 235	780
AGC TTC TGT TAC CTT GTC ATC ATC CGC ACC CTG CTC CAG GCA CGC AAC Ser Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn 240 245 250 255	828
TTT GAG CGC AAC AAG GCC ATC AAG GTG ATC ATC GCT GTG GTC GTG GTC Phe Glu Arg Asn Lys Ala Ile Lys Val Ile Ile Ala Val Val Val Val 260 265 270	876
TTC ATA GTC TTC CAG CTG CCC TAC AAT GGG GTG GTC CTG GCC CAG ACG Phe Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr 275 280 285	924
GTG GCC AAC TTC AAC ATC ACC AGT AGC ACC TGT GAG CTC AGT AAG CAA Val Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln 290 295 300	972
CTC AAC ATC GCC TAC GAC GTC ACC TAC AGC CTG GCC TGC GTC CGC TGC Leu Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys 305 310 315	1020
TGC GTC AAC CCT TTC TTG TAC GCC TTC ATC GGC GTC AAG TTC CGC AAC Cys Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn 320 325 330 335	1068
GAT ATC TTC AAG CTC TTC AAG GAC CTG GGC TGC CTC AGC CAG GAG CAG Asp Ile Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln 340 345 350	1116
CTC CGG CAG TGG TCT TCC TGT CGG CAC ATC CGG CGC TCC TCC ATG AGT Leu Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser 355 360 365	1164
GTG GAG GCC GAG ACC ACC ACC ACC TTC TCC CCA TAGGCGACTC TTCTGCCTGG Val Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro 370 375	1217
ACTAGAGGGA CCTCTCCAG GGTCCCTGGG GTGGGGATAG GGAGCAGATG CAATGACTCA	1277
GGACATCCCC CCGCCAAAAG CTGCTCAGGG GAAAAAGCAG CTCTCCCTC AGAGTGCAAG	1337

-54-

CCCCTGCTCC AGAAGATAGC TTCACCCCAA TCCCAGCTAC CTCAACCAAT GCCAAAAAAA 1397  
 GACAGGGCTG ATAAGCTAAC ACCAGACAGA CAACACTGGG AAACAGAGGC TATTGTCCCC 1457  
 TAAACCAAAA ACTGAAAGTG AAAGTCCAGA AACTGTTCCC ACCTGCTGGA GTGAAGGGGC 1517  
 CAAGGAGGGT GAGTGCAAGG GCGTGGGAG TGGCCTGAAG AGTCCTCTGA ATGAACCTTC 1577  
 TGGCCTCCCA CAGACTCAA TGCTCAGACC AGCTCTCCG AAAACCAGGC CTTATCTCCA 1637  
 AGACCAGAGA TAGTGGGGAG ACTTCTTGGC TTGGTGAGGA AAAGCGGACA TCAGCTGGTC 1697  
 AAACAACTC TCTGAACCCC TCCCTCCATC GTTTTCTTCA CTGTCCTCCA AGCCAGCGGG 1757  
 AATGGCAGCT GCCACGCCGC CCTAAAAGCA CACTCATCCC CTCACITGCC GCGTCGCCCT 1817  
 CCCAGGCTCT CAACAGGGGA GAGTGTGGTG TTTCCTGCAG GCCAGGCCAG CTGCCTCCGC 1877  
 GTGATCAAAG CCACACTCTG GGCTCCAGAG TGGGGATGAC ATGCACTCAG CTCTTGGCTC 1937  
 CACTGGGATG GGAGGAGAGG ACAAGGGAAA TGTCAGGGGC GGGGAGGGTG ACAGTGGCCG 1997  
 CCCAAGGCCA CGAGCTTGT CTTTGTCTT TGTCACAGGG ACTGAAAACC TCTCCTCATG 2057  
 TTCTGCTTTC GATTGTTAA GAGAGCAACA TTTTACCCAC ACACAGATAA AGTTTTCCCT 2117  
 TGAGGAAACA ACAGCTTTAA AAAAAAAAAA GGAATTC 2154

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 378 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asp Leu Gly Lys Pro Met Lys Ser Val Leu Val Val Ala Leu Leu  
 1 5 10 15  
 Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp Tyr  
 20 25 30  
 Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu Cys  
 35 40 45  
 Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile Met  
 50 55 60



-55-

Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val Val  
 65 70 75 80

Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr Tyr  
 85 90 95

Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu Pro  
 100 105 110

Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His Phe  
 115 120 125

Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly Met  
 130 135 140

Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val Gln  
 145 150 155 160

Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser Lys  
 165 170 175

Leu Ser Cys Val Gly Ser Ala Ile Leu Ala Thr Val Leu Ser Ile Pro  
 180 185 190

Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala Met  
 195 200 205

Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile Gln  
 210 215 220

Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met Ser  
 225 230 235 240

Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn Phe  
 245 250 255

Glu Arg Asn Lys Ala Ile Lys Val Ile Ile Ala Val Val Val Val Phe  
 260 265 270

Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr Val  
 275 280 285

Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln Leu  
 290 295 300

Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys Cys  
 305 310 315 320

Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn Asp  
 325 330 335

-56-

Ile Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln Leu  
 340 345 350

Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser Val  
 355 360 365

Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro  
 370 375

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1643 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 34..1116

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGAATTCCTT GATATACACC TGGACCACCA CCA ATG GAT ATA CAA ATG GCA AAC	54
Met Asp Ile Gln Met Ala Asn	
1 5	
AAT TTT ACT CCG CCC TCT GCA ACT CCT CAG GGA AAT GAC TGT GAC CTC	102
Asn Phe Thr Pro Pro Ser Ala Thr Pro Gln Gly Asn Asp Cys Asp Leu	
10 15 20	
TAT GCA CAT CAC AGC ACG GCC AGG ATA GTA ATG CCT CTG CAT TAC AGC	150
Tyr Ala His His Ser Thr Ala Arg Ile Val Met Pro Leu His Tyr Ser	
25 30 35	
CTC GTC TTC ATC ATT GGG CTC GTG GGA AAC TTA CTA GCC TTG GTC GTC	198
Leu Val Phe Ile Ile Gly Leu Val Gly Asn Leu Leu Ala Leu Val Val	
40 45 50 55	
ATT GTT CAA AAC AGG AAA AAA ATC AAC TCT ACC ACC CTC TAT TCA ACA	246
Ile Val Gln Asn Arg Lys Lys Ile Asn Ser Thr Thr Leu Tyr Ser Thr	
60 65 70	
AAT TTG GTG ATT TCT GAT ATA CTT TTT ACC ACG GCT TTG CCT ACA CGA	294
Asn Leu Val Ile Ser Asp Ile Leu Phe Thr Thr Ala Leu Pro Thr Arg	
75 80 85	

-57-

ATA GCC TAC TAT GCA ATG GGC TTT GAC TGG AGA ATC GGA GAT GCC TTG Ile Ala Tyr Tyr Ala Met Gly Phe Asp Trp Arg Ile Gly Asp Ala Leu 90 95 100	342
TGT AGG ATA ACT GCG CTA GTG TTT TAC ATC AAC ACA TAT GCA GGT GTG Cys Arg Ile Thr Ala Leu Val Phe Tyr Ile Asn Thr Tyr Ala Gly Val 105 110 115	390
AAC TTT ATG ACC TGC CTG AGT ATT GAC CGC TTC ATT GCT GTG GTG CAC Asn Phe Met Thr Cys Leu Ser Ile Asp Arg Phe Ile Ala Val Val His 120 125 130 135	438
CCT CTA CGC TAC AAC AAG ATA AAA AGG ATT GAA CAT GCA AAA GGC GTG Pro Leu Arg Tyr Asn Lys Ile Lys Arg Ile Glu His Ala Lys Gly Val 140 145 150	486
TGC ATA TTT GTC TGG ATT CTA GTA TTT GCT CAG ACA CTC CCA CTC CTC Cys Ile Phe Val Trp Ile Leu Val Phe Ala Gln Thr Leu Pro Leu Leu 155 160 165	534
ATC AAC CCT ATG TCA AAG CAG GAG GCT GAA AGG ATT ACA TGC ATG GAG Ile Asn Pro Met Ser Lys Gln Glu Ala Glu Arg Ile Thr Cys Met Glu 170 175 180	582
TAT CCA AAC TTT GAA GAA ACT AAA TCT CTT CCC TGG ATT CTG CTT GGG Tyr Pro Asn Phe Glu Glu Thr Lys Ser Leu Pro Trp Ile Leu Leu Gly 185 190 195	630
GCA TGT TTC ATA GGA TAT GTA CTT CCA CTT ATA ATC ATT CTC ATC TGC Ala Cys Phe Ile Gly Tyr Val Leu Pro Leu Ile Ile Ile Leu Ile Cys 200 205 210 215	678
TAT TCT CAG ATC TGC TGC AAA CTC TTC AGA ACT GCC AAA CAA AAC CCA Tyr Ser Gln Ile Cys Cys Lys Leu Phe Arg Thr Ala Lys Gln Asn Pro 220 225 230	726
CTC ACT GAG AAA TCT GGT GTA AAC AAA AAG GCT CTC AAC ACA ATT ATT Leu Thr Glu Lys Ser Gly Val Asn Lys Lys Ala Leu Asn Thr Ile Ile 235 240 245	774
CTT ATT ATT GTT GTG TTT GTT CTC TGT TTC ACA CCT TAC CAT GTT GCA Leu Ile Ile Val Val Phe Val Leu Cys Phe Thr Pro Tyr His Val Ala 250 255 260	822
ATT ATT CAA CAT ATG ATT AAG AAG CTT CGT TTC TCT AAT TTC CTG GAA Ile Ile Gln His Met Ile Lys Lys Leu Arg Phe Ser Asn Phe Leu Glu 265 270 275	870
TGT AGC CAA AGA CAT TCG TTC CAG ATT TCT CTG CAC TTT ACA GTA TGC Cys Ser Gln Arg His Ser Phe Gln Ile Ser Leu His Phe Thr Val Cys 280 285 290 295	918

-58-

CTG ATG AAC TTC AAT TGC TGC ATG GAC CCT TTT ATC TAC TTC TTT GCA 966  
 Leu Met Asn Phe Asn Cys Cys Met Asp Pro Phe Ile Tyr Phe Phe Ala  
 300 305 310

TGT AAA GGG TAT AAG AGA AAG GTT ATG AGG ATG CTG AAA CGG CAA GTC 1014  
 Cys Lys Gly Tyr Lys Arg Lys Val Met Arg Met Leu Lys Arg Gln Val  
 315 320 325

AGT GTA TCG ATT TCT AGT GCT GTG AAG TCA GCC CCT GAA GAA AAT TCA 1062  
 Ser Val Ser Ile Ser Ser Ala Val Lys Ser Ala Pro Glu Glu Asn Ser  
 330 335 340

CGT GAA ATG ACA GAA ACG CAG ATG ATG ATA CAT TCC AAG TCT TCA AAT 1110  
 Arg Glu Met Thr Glu Thr Gln Met Met Ile His Ser Lys Ser Ser Asn  
 345 350 355

GGA AAG TGAATGGAT TGTATTTTGG TTTATAGTGA CGTAACTGT ATGACAACT 1166  
 Gly Lys  
 360

TTGCAGGACT TCCCTTATAA AGCAAATAA TTGTTTCAGCT TCCAATTAGT ATTCTTTTAT 1226

ATTTCTTTCA TTGGGCGCTT TCCCATCTCC AACTCGGAAG TAAGCCCAAG AGAACAACAT 1286

AAAGCAAACA ACATAAAGCA CAATAAAAT GCAAATAAAT ATTTTCATTT TTATTTGTAA 1346

ACGAATACAC CAAAAGGAGG CGCTCTTAAT AACTCCCAAT GTAAAAAGTT TTGTTTTAAT 1406

AAAAAATTAA TTATTATTCT TGCCAACAAA TGGCTAGAAA GGACTGAATA GATTATATAT 1466

TGCCAGATGT TAATACTGTA ACATACTTTT TAAATAACAT ATTTCTTAAA TCCAAATTTC 1526

TCTCAATGTT AGATTTAATT CCCTCAATAA CACCAATGTT TTGTTTGTGTT TCGTTCTGGG 1586

TCATAAACT TTGTTAAGGA ACTCTTTTGG AATAAAGAGC AGGATGCTGC GGAATTC 1643

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 361 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Asp Ile Gln Met Ala Asn Asn Phe Thr Pro Pro Ser Ala Thr Pro  
 1 5 10 15

-59-

Gln Gly Asn Asp Cys Asp Leu Tyr Ala His His Ser Thr Ala Arg Ile  
 20 25 30

Val Met Pro Leu His Tyr Ser Leu Val Phe Ile Ile Gly Leu Val Gly  
 35 40 45

Asn Leu Leu Ala Leu Val Val Ile Val Gln Asn Arg Lys Lys Ile Asn  
 50 55 60

Ser Thr Thr Leu Tyr Ser Thr Asn Leu Val Ile Ser Asp Ile Leu Phe  
 65 70 75 80

Thr Thr Ala Leu Pro Thr Arg Ile Ala Tyr Tyr Ala Met Gly Phe Asp  
 85 90 95

Trp Arg Ile Gly Asp Ala Leu Cys Arg Ile Thr Ala Leu Val Phe Tyr  
 100 105 110

Ile Asn Thr Tyr Ala Gly Val Asn Phe Met Thr Cys Leu Ser Ile Asp  
 115 120 125

Arg Phe Ile Ala Val Val His Pro Leu Arg Tyr Asn Lys Ile Lys Arg  
 130 135 140

Ile Glu His Ala Lys Gly Val Cys Ile Phe Val Trp Ile Leu Val Phe  
 145 150 155 160

Ala Gln Thr Leu Pro Leu Leu Ile Asn Pro Met Ser Lys Gln Glu Ala  
 165 170 175

Glu Arg Ile Thr Cys Met Glu Tyr Pro Asn Phe Glu Glu Thr Lys Ser  
 180 185 190

Leu Pro Trp Ile Leu Leu Gly Ala Cys Phe Ile Gly Tyr Val Leu Pro  
 195 200 205

Leu Ile Ile Ile Leu Ile Cys Tyr Ser Gln Ile Cys Cys Lys Leu Phe  
 210 215 220

Arg Thr Ala Lys Gln Asn Pro Leu Thr Glu Lys Ser Gly Val Asn Lys  
 225 230 235 240

Lys Ala Leu Asn Thr Ile Ile Leu Ile Ile Val Val Phe Val Leu Cys  
 245 250 255

Phe Thr Pro Tyr His Val Ala Ile Ile Gln His Met Ile Lys Lys Leu  
 260 265 270

Arg Phe Ser Asn Phe Leu Glu Cys Ser Gln Arg His Ser Phe Gln Ile  
 275 280 285

-60-

Ser Leu His Phe Thr Val Cys Leu Met Asn Phe Asn Cys Cys Met Asp  
 290 295 300

Pro Phe Ile Tyr Phe Phe Ala Cys Lys Gly Tyr Lys Arg Lys Val Met  
 305 310 315 320

Arg Met Leu Lys Arg Gln Val Ser Val Ser Ile Ser Ser Ala Val Lys  
 325 330 335

Ser Ala Pro Glu Glu Asn Ser Arg Glu Met Thr Glu Thr Gln Met Met  
 340 345 350

Ile His Ser Lys Ser Ser Asn Gly Lys  
 355 360

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1164 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 14..703

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GAATTCGCA GCC ATG ACC CCG CAG CTT CTC CTG GCC CTT GTC CTC TGG	49
Met Thr Pro Gln Leu Leu Ala Leu Val Leu Trp	
1 5 10	
GCC AGC TGC CCG CCC TGC AGT GGA AGG AAA GGG CCC CCA GCA GCT CTG	97
Ala Ser Cys Pro Pro Cys Ser Gly Arg Lys Gly Pro Pro Ala Ala Leu	
15 20 25	
ACA CTG CCC CCG GTG CAA TGC CGA GCC TCT CGG TAC CCG ATC GCC GTG	145
Thr Leu Pro Arg Val Gln Cys Arg Ala Ser Arg Tyr Pro Ile Ala Val	
30 35 40	
GAT TGC TCC TGG ACC CTG CCG CCT GCT CCA AAC TCC ACC AGC CCC GGT	193
Asp Cys Ser Trp Thr Leu Pro Pro Ala Pro Asn Ser Thr Ser Pro Gly	
45 50 55 60	
GTC CGT GGA TTG CGA CGT ACA GGC TCG GCA TGG CTG CCC GGG GCC ACA	241
Val Arg Gly Leu Arg Arg Thr Gly Ser Ala Trp Leu Pro Gly Ala Thr	
65 70 75	

-61-

GCG TGG CCC TGC CTG CAG CAG ACG CCA ACG TCC ACC AGC TGC ACC ATC Ala Trp Pro Cys Leu Gln Gln Thr Pro Thr Ser Thr Ser Cys Thr Ile 80 85 90	289
ACG GAT GTC CAG CTG TTC TCC ATG GCT CCC TAC GTG CTC AAT GTC ACC Thr Asp Val Gln Leu Phe Ser Met Ala Pro Tyr Val Leu Asn Val Thr 95 100 105	337
GCC GTC CAC CCC TGG GGC TCC AGC AGC AGC TTC GTG CCT TTC ATA ACA Ala Val His Pro Trp Gly Ser Ser Ser Ser Phe Val Pro Phe Ile Thr 110 115 120	385
GAG CAC ATC ATC AAG CCC GAC CCT CCA GAA GGC GTG CGC CTA AGC CCC Glu His Ile Ile Lys Pro Asp Pro Pro Glu Gly Val Arg Leu Ser Pro 125 130 135 140	433
CTC GCT GAG CGC CAC GTA CAG GTG CAG TGG GAG CCT CCC GGG TCC TGG Leu Ala Glu Arg His Val Gln Val Gln Trp Glu Pro Pro Gly Ser Trp 145 150 155	481
CCC TTC CCA GAG ATC TTC TCA CTG AAG TAC TGG ATC CGT TAC AAG CGT Pro Phe Pro Glu Ile Phe Ser Leu Lys Tyr Trp Ile Arg Tyr Lys Arg 160 165 170	529
CAG GGA GCT GCG CGC TTC CAC CGG GTG GGG CCC ATT GAA GCC ACG TCC Gln Gly Ala Ala Arg Phe His Arg Val Gly Pro Ile Glu Ala Thr Ser 175 180 185	577
TTC ATC CTC AGG GCT GTG CGG CCC CGA GCC AGG TAC TAC GTC CAA GTG Phe Ile Leu Arg Ala Val Arg Pro Arg Ala Arg Tyr Tyr Val Gln Val 190 195 200	625
GCG GCT CAG GAC CTC ACA GAC TAC GGG GAA CTG AGT GAC TGG AGT CTC Ala Ala Gln Asp Leu Thr Asp Tyr Gly Glu Leu Ser Asp Trp Ser Leu 205 210 215 220	673
CCC GCC ACT GCC ACA ATG AGC CTG GGC AAG TAGCAAGGGC TTCCCGCTGC Pro Ala Thr Ala Thr Met Ser Leu Gly Lys 225 230	723
CTCCAGACAG CACCTGGGTC CTCGCCACCC TAAGCCCCGG GACACCTGTT GGAGGGCGGA	783
TGGGATCTGC CTAGCCTGGG CTGGAGTCCT TGCTTTGCTG CTGCTGAGCT GCCGGGCAAC	843
CTCAGATGAC CGACTTTTCC CTTTGAGCCT CAGTTTCTCT AGCTGAGAAA TGGAGATGTA	903
CTACTCTCTC CTTTACCTTT ACCTTTACCA CAGTGCAGGG CTGACTGAAC TGCTACTGTG	963
AGATATTTTT TATTGTTTAA TTAGAAAAGA ATTGTTGTG GGCCTGGGCGC AGTGGATCGC	1023
ACCTGTAATC CCAGTCACTG GGAAGCCGAC GTGGGTGGGT AGCTTGAGGC CAGGAGCTCG	1083

-62-

AAACCAGTCC GGGCCACACA GCAAGACCCC ATCTCTAAAA AATTAATATA AATATAAAAT 1143  
 AAAAAAAAAA AAAAGGAATT C 1164

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 230 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Thr Pro Gln Leu Leu Leu Ala Leu Val Leu Trp Ala Ser Cys Pro  
 1 5 10 15  
 Pro Cys Ser Gly Arg Lys Gly Pro Pro Ala Ala Leu Thr Leu Pro Arg  
 20 25 30  
 Val Gln Cys Arg Ala Ser Arg Tyr Pro Ile Ala Val Asp Cys Ser Trp  
 35 40 45  
 Thr Leu Pro Pro Ala Pro Asn Ser Thr Ser Pro Gly Val Arg Gly Leu  
 50 55 60  
 Arg Arg Thr Gly Ser Ala Trp Leu Pro Gly Ala Thr Ala Trp Pro Cys  
 65 70 75 80  
 Leu Gln Gln Thr Pro Thr Ser Thr Ser Cys Thr Ile Thr Asp Val Gln  
 85 90 95  
 Leu Phe Ser Met Ala Pro Tyr Val Leu Asn Val Thr Ala Val His Pro  
 100 105 110  
 Trp Gly Ser Ser Ser Ser Phe Val Pro Phe Ile Thr Glu His Ile Ile  
 115 120 125  
 Lys Pro Asp Pro Pro Glu Gly Val Arg Leu Ser Pro Leu Ala Glu Arg  
 130 135 140  
 His Val Gln Val Gln Trp Glu Pro Pro Gly Ser Trp Pro Phe Pro Glu  
 145 150 155 160  
 Ile Phe Ser Leu Lys Tyr Trp Ile Arg Tyr Lys Arg Gln Gly Ala Ala  
 165 170 175



-63-

Arg Phe His Arg Val Gly Pro Ile Glu Ala Thr Ser Phe Ile Leu Arg  
180 185 190

Ala Val Arg Pro Arg Ala Arg Tyr Tyr Val Gln Val Ala Ala Gln Asp  
195 200 205

Leu Thr Asp Tyr Gly Glu Leu Ser Asp Trp Ser Leu Pro Ala Thr Ala  
210 215 220

Thr Met Ser Leu Gly Lys  
225 230

***WHAT IS CLAIMED IS:***

1. A DNA segment coding for a polypeptide having an amino acid sequence corresponding to a polypeptide selected from the group consisting of EBI 1, EBI 2, and EBI 3 polypeptides.
2. The DNA segment according to claim 1, wherein the DNA segment has a sequence selected from the group consisting of sequences set forth in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5; or allelic, mutant or species variation thereof.
3. The DNA segment according to claim 1, wherein the DNA segment has an allelic variation of a sequence selected from the group consisting of sequences set forth in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.
4. The DNA segment according to claim 1, wherein the DNA segment encodes an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof.
5. The DNA segment according to claim 1, wherein the DNA segment has a sequence selected from the group consisting of sequences set forth in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.
6. The DNA segment according to claim 1, wherein the DNA segment encodes an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6.
7. A substantially pure polypeptide having an amino acid sequence corresponding to a polypeptide selected from the group consisting of EBI 1, EBI 2, and EBI 3 polypeptides.

-65-

8. The polypeptide according to claim 7, wherein the polypeptide has an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof.

9. A nucleic acid probe for the detection of the presence of Epstein Barr Virus in a sample comprising the DNA segment according to claim 1 or at least 20 contiguous nucleotides thereof.

10. The nucleic acid probe according to claim 9, wherein the DNA segment has a nucleic acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, or at least 20 contiguous nucleotides thereof.

11. The nucleic acid probe according to claim 9, wherein the probe encodes an amino acid sequence selected from the group consisting of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or at least 7 contiguous amino acids thereof.

12. A method of detecting Epstein Barr virus in a sample comprising:  
a) contacting said sample with the nucleic acid probe according to claim 9, under conditions such that hybridization occurs, and  
b) detecting the presence of said probe bound to RNA.

13. A kit detecting the presence of Epstein Barr virus in a sample comprising at least one container means having disposed therein the nucleic acid probe according to claim 9.

14. A recombinant DNA molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the DNA segment according to claim 1.

15. A cell that contains the DNA molecule according to claim 14.

16. A recombinant DNA molecule comprising a vector and the DNA segment according to claim 1.

17. A cell that contains the recombinant DNA molecule according to claim 16.

18. A recombinant DNA molecule comprising a transcriptional region functional in a cell, a sequence complementary to an RNA sequence encoding an amino acid sequence corresponding to the polypeptide of claim 7, and a transcriptional termination region functional in said cell.

19. A cell that contains the recombinant DNA molecule according to claim 18.

20. An antibody having binding affinity to a polypeptide having an amino acid sequence selected from the group consisting of EBI 1, EBI 2, and EBI 3 polypeptides, or a binding fragment thereof.

21. The antibody according to claim 20, wherein said polypeptide has an amino acid sequence selected from the group of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof.

22. The antibody according to claim 20, wherein said antibody is a monoclonal antibody.

23. A method of detecting a polypeptide selected from the group consisting of EBI 1, EBI 2, EBI 3 in a sample, comprising:

-67-

- a) contacting said sample with an antibody according to claim 20, under conditions such that immunocomplexes form, and
- b) detecting the presence of said antibody bound to said polypeptide.

24. A diagnostic kit comprising:

- i) a first container means containing the antibody according to claim 20, and
- ii) second container means containing a conjugate comprising a binding partner of said monoclonal antibody and a label.

25. A hybridoma which produces the monoclonal antibody according to claim 22, or binding fragment thereof.

26. The hybridoma according to claim 25, wherein said polypeptide has an amino acid sequence selected from the group of sequences set forth in SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or mutant or species variation thereof, or at least 7 contiguous amino acids thereof.

1/17

GGAATTCGGT AGTGGGAGGC CGGGCACAGC CTCCTGTGT GGTTTTACCG CCCAGAGAGC	60
* **	
GTC ATG GAC CTG GCG AAA CCA ATG AAA AGC GTG CTG GTG GTG GCT CTC	108
Met Asp Leu Gly Lys Pro Met Lys Ser Val Leu Val Val Ala Leu	
1 5 10 15	
CTT GTC ATT TTC CAG GTA TGC CTG TGT CAA GAT GAG GTC ACG GAC GAT	156
Leu Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp	
20 25 30	
TAC ATC GGA GAC AAC ACC ACA GTG GAC TAC ACT TTG TTC GAG TCT TTG	204
Tyr Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu	
35 CHO ### ### 40 45	
TGC TCC AAG AAG GAC GTG CCG AAC TTT AAA GCC TGG TTC CTC CCT ATC	252
Cys Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile	
50 55 60	
ATG TAC TCC ATC ATT TGT TTC GTG GGC CTA CTG GGC AAT GGG CTG GTC	300
Met Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val	
65 70 75	
GTG TTG ACC TAT ATC TAT TTC AAG AGG CTC AAG ACC ATG ACC GAT ACC	348
Val Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr	
80 85 90 95	
TAC CTG CTC AAC CTG GCG GTG GCA GAC ATC CTC TTC CTC CTG ACC CTT	396
Tyr Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu	
100 105 110	
CCC TTC TGG GCC TAC AGC GCG GCC AAG TCC TGG GTC TTC GGT GTC CAC	444
Pro Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His	
115 120 125	
TTT TGC AAG CTC ATC TTT GCC ATC TAC AAG ATG AGC TTC TTC AGT GGC	492
Phe Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly	
130 135 140	
ATG CTC CTA CTT CTT TGC ATC AGC ATT GAC CGC TAC GTG GCC ATC GTC	540
Met Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val	
145 150 155	

FIG.1A-1

SUBSTITUTE SHEET (RULE 26)

2/17

CAG GCT GTC TCA GCT CAC CGC CAC CGT GCC CGC GTC CTT CTC ATC AGC Gln Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser	588
160 165 170 175	
AAG CTG TCC TGT GTG GGC AGC GCC ATA CTA GCC ACA GTG CTC TCC ATC Lys Leu Ser Cys Val Gly Ser Ala Ile Leu Ala Thr Val Leu Ser Ile	636
180 185 190	
CCA GAG CTC CTG TAC AGT GAC CTC CAG AGG AGC AGC AGT GAG CAA GCG Pro Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala	684
195 200 205	
ATG CGA TGC TCT CTC ATC ACA GAG CAT GTG GAG GCC TTT ATC ACC ATC Met Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile	732
210 215 220	
CAG GTG GCC CAG ATG GTG ATC GGC TTT CTG GTC CCC CTG CTG GCC ATG Gln Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met	780
225 230 235	
AGC TTC TGT TAC CTT GTC ATC ATC CGC ACC CTG CTC CAG GCA CGC AAC Ser Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn	828
240 245 250 255	
TTT GAG CGC AAC AAG GCC ATC AAG GTG ATC ATC GCT GTG GTC GTG GTC Phe Glu Arg Asn Lys Ala Ile Lys Val Ile Ile Ala Val Val Val Val	876
260 265 270	
TTC ATA GTC TTC CAG CTG CCC TAC AAT GGG GTG GTC CTG GCC CAG ACC Phe Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr	924
275 280 285	
GTG GCC AAC TTC AAC ATC ACC AGT AGC ACC TGT GAG CTC AGT AAG CAA Val Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln	972
290 CHO ### ### 295 300	
CTC AAC ATC GCC TAC GAC GTC ACC TAC AGC CTG GCC TGC GTC CGC TGC Leu Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys	1020
305 310 315	

FIG.1A-2

SUBSTITUTE SHEET (RULE 26)

3/17

TGC GTC AAC CCT TTC TTG TAC GCC TTC ATC GGC GTC AAG TTC CGC AAC	1068
Cys Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn	
320 325 330 335	
GAT ATC TTC AAG CTC TTC AAG GAC CTG GGC TGC CTC AGC CAG GAG CAG	1116
Asp Ile Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln	
340 345 350	
CTC CGG CAG TGG TCT TCC TGT CGG CAC ATC CGG CGC TCC TCC ATG AGT	1164
Leu Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser	
355 360 365	
GTG GAG GCC GAG ACC ACC ACC ACC TTC TCC CCA TAGGCGACTC TTCTGCCTGG	1217
Val Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro ***	
370 375	
ACTAGAGGGA CCTCTCCCAG GGTCCCTGGG GTGGGGATAG GGAGCAGATG CAATGACTCA	1277
GGACATCCCC CCGCCAAAAG CTGCTCAGGG GAAAAAGCAG CTCTCCCCTC AGAGTGCAAG	1337
CCCCTGCTCC AGAAGATAGC TTCACCCCAA TCCAGCTAC CTCAACCAAT GCCAAAAAAA	1397
GACAGGGCTG ATAAGCTAAC ACCAGACAGA CAACACTGGG AAACAGAGGC TATTGTCCCC	1457
TAAACCAAAA ACTGAAAGTG AAAGTCCAGA AACTGTTCCC ACCTGCTGGA GTGAAGGGGC	1517
CAAGGAGGGT GAGTGCAAGG GGGGTGGGAG TGGCTGAAG AGTCCTCTGA ATGAACCTTC	1577
TGGCTCCCA CAGACTCAA TGCTCAGACC AGCTCTTCCG AAAACCAGGC CTTATCTCCA	1637
AGACCAGAGA TAGTGGGGAG ACTTCTTGGC TTGGTGAGGA AAAGCGGACA TCAGCTGGTC	1697
AAACAAACTC TCTGAACCCC TCCCTCCATC GTTTTCTTCA CTGTCCTCCA AGCCAGCGGG	1757
AATGGCAGCT GCCACGCCGC CCTAAAAGCA CACTCATCCC CTCATTGCC GCGTCGCCCT	1817
CCCAGGCTCT CAACAGGGGA GAGTGTGGTG TTTCTGCAG GCCAGGCCAG CTGCCTCCGC	1877
GTGATCAAAG CCACACTCTG GGCTCCAGAG TGGGGATGAC ATGCACTCAG CTCTTGGCTC	1937

FIG. 1A-3



4/17

CACTGGGATG GGAGGAGAGG ACAAGGGAAA TGTGAGGGC GGGGAGGGTG ACAGTGGCCG 1997  
CCCAAGGCCA CGAGCTTGT CTTTGTCTT TGTACAGGG ACTGAAAACC TCTCCTCATG 2057  
TTCTGCTTTC GATTCGTAA GAGAGCAACA TTTTACCCAC ACACAGATAA AGTTTTCCCT 2117  
TGAGGAAACA ACAGCTTTAA AAAAAAAAAA GGAATTC 2154

FIG.1A-4

5/17

GGAATTCCT GATATACACC TGGACCACCA CCA ATG GAT ATA CAA ATG GCA AAC 54

\* \*\*

Met Asp Ile Gln Met Ala Asn

1

5

AAT TTT ACT CCG CCC TCT GCA ACT CCT CAG GGA AAT GAC TGT GAC CTC 102

Asn Phe Thr Pro Pro Ser Ala Thr Pro Gln Gly Asn Asp Cys Asp Leu

CHO ### ###

10

15

20

TAT GCA CAT CAC AGC AGC GCC AGG ATA GTA ATG CCT CTG CAT TAC AGC 150

Tyr Ala His His Ser Thr Ala Arg Ile Val Met Pro Leu His Tyr Ser

25

30

35

CTC GTC TTC ATC ATT GGG CTC GTG GGA AAC TTA CTA GCC TTG GTC GTC 198

Leu Val Phe Ile Ile Gly Leu Val Gly Asn Leu Leu Ala Leu Val Val

40

45

50

55

ATT GTT CAA AAC AGG AAA AAA ATC AAC TCT ACC ACC CTC TAT TCA ACA 246

Ile Val Gln Asn Arg Lys Lys Ile Asn Ser Thr Thr Leu Tyr Ser Thr

60

65

70

AAT TTG GTG ATT TCT GAT ATA CTT TTT ACC ACG GCT TTG CCT ACA CGA 294

Asn Leu Val Ile Ser Asp Ile Leu Phe Thr Thr Ala Leu Pro Thr Arg

75

80

85

ATA GCC TAC TAT GCA ATG GGC TTT GAC TGG AGA ATC GGA GAT GCC TTG 342

Ile Ala Tyr Tyr Ala Met Gly Phe Asp Trp Arg Ile Gly Asp Ala Leu

90

95

100

TGT AGG ATA ACT GCG CTA GTG TTT TAC ATC AAC ACA TAT GCA GGT GTG 390

Cys Arg Ile Thr Ala Leu Val Phe Tyr Ile Asn Thr Tyr Ala Gly Val

105

110

115

FIG.1B-1

SUBSTITUTE SHEET (RULE 26)

6/17

AAC TTT ATG ACC TGC CTG AGT ATT GAC CGC TTC ATT GCT GTG GTG CAC 438

Asn Phe Met Thr Cys Leu Ser Ile Asp Arg Phe Ile Ala Val Val His  
 120 125 130 135

CCT CTA CGC TAC AAC AAG ATA AAA AGG ATT GAA CAT GCA AAA GGC GTG 486

Pro Leu Arg Tyr Asn Lys Ile Lys Arg Ile Glu His Ala Lys Gly Val  
 140 145 150

TGC ATA TTT GTC TGG ATT CTA GTA TTT GCT CAG ACA CTC CCA CTC CTC 534

Cys Ile Phe Val Trp Ile Leu Val Phe Ala Gln Thr Leu Pro Leu Leu  
 155 160 165

ATC AAC CCT ATG TCA AAG CAG GAG GCT GAA AGG ATT ACA TGC ATG GAG 582

Ile Asn Pro Met Ser Lys Gln Glu Ala Glu Arg Ile Thr Cys Met Glu  
 170 175 180

TAT CCA AAC TTT GAA GAA ACT AAA TCT CTT CCC TGG ATT CTG CTT GGG 630

Tyr Pro Asn Phe Glu Glu Thr Lys Ser Leu Pro Trp Ile Leu Leu Gly  
 185 190 195

GCA TGT TTC ATA GGA TAT GTA CTT CCA CTT ATA ATC ATT CTC ATC TGC 678

Ala Cys Phe Ile Gly Tyr Val Leu Pro Leu Ile Ile Ile Leu Ile Cys  
 200 205 210 215

TAT TCT CAG ATC TGC TGC AAA CTC TTC AGA ACT GCC AAA CAA AAC CCA 726

Tyr Ser Gln Ile Cys Cys Lys Leu Phe Arg Thr Ala Lys Gln Asn Pro  
 220 225 230

CTC ACT GAG AAA TCT GGT GTA AAC AAA AAG GCT CTC AAC ACA ATT ATT 774

Leu Thr Glu Lys Ser Gly Val Asn Lys Lys Ala Leu Asn Thr Ile Ile  
 235 240 245

CTT ATT ATT GTT GTG TTT GTT CTC TGT TTC ACA CCT TAC CAT GTT GCA 822

Leu Ile Ile Val Val Phe Val Leu Cys Phe Thr Pro Tyr His Val Ala  
 250 255 260

FIG.1B-2

SUBSTITUTE SHEET (RULE 26)

7/17

ATT ATT CAA CAT ATG ATT AAG AAG CTT CGT TTC TCT AAT TTC CTG GAA 870  
Ile Ile Gln His Met Ile Lys Lys Leu Arg Phe Ser Asn Phe Leu Glu  
 265 270 275  
 TGT AGC CAA AGA CAT TCG TTC CAG ATT TCT CTG CAC TTT ACA GTA TGC 918  
 Cys Ser Gln Arg His Ser Phe Gln Ile Ser Leu His Phe Thr Val Cys  
 280 285 290 295  
 CTG ATG AAC TTC AAT TGC TGC ATG GAC CCT TTT ATC TAC TTC TTT GCA 966  
Leu Met Asn Phe Asn Cys Cys Met Asp Pro Phe Ile Tyr Phe Phe Ala  
 300 305 310  
 TGT AAA GGG TAT AAG AGA AAG GTT ATG AGG ATG CTG AAA CGG CAA GTC 1014  
Cys Lys Gly Tyr Lys Arg Lys Val Met Arg Met Leu Lys Arg Gln Val  
 315 320 325  
 AGT GTA TCG ATT TCT AGT GCT GTG AAG TCA GCC CCT GAA GAA AAT TCA 1062  
 Ser Val Ser Ile Ser Ser Ala Val Lys Ser Ala Pro Glu Glu Asn Ser  
 330 335 340  
 CGT GAA ATG ACA GAA ACG CAG ATG ATG ATA CAT TCC AAG TCT TCA AAT 1110  
 Arg Glu Met Thr Glu Thr Gln Met Met Ile His Ser Lys Ser Ser Asn  
 345 350 355  
 GGA AAG TGAAATGCAT TGTATTTTGG TTTATAGTGA CGTAAACTGT ATGACAAACT 1166  
 Gly Lys \*\*\*  
 360  
 TTGCAGGACT TCCCTTATAA AGCAAAATAA TTGTTTCAGCT TCCAATTAGT ATTCTTTTAT 1226  
 ATTTCTTTCA TTGGGCGCTT TCCCATCTCC AACTCGGAAG TAAGCCCAAG AGAACAACAT 1286  
 AAAGCAAACA ACATAAAGCA CAATAAAAAT GCAAATAAAT ATTTTCATTT TTATTTGTAA 1346

FIG.1B-3

SUBSTITUTE SHEET (RULE 26)

8/17

ACGAATACAC CAAAAGGAGG CGCTCTTAAT AACTCCCAAT GTAAAAAGTT TTGTTTTAAT 1406

AAAAAATTAA TTATTATTCT TGCCAACAAA TGGCTAGAAA GGACTGAATA GATTATATAT 1466

TGCCAGATGT TAATACTGTA ACATACTTTT TAAATAACAT ATTCTTAAA TCCAAATTC 1526

TCICAATGTT AGATTTAATT CCTCAATAA CACCAATGTT TTGTTTTGTT TCGTCTGGG 1586

TCATAAACT TTGTTAAGGA ACTCTTTTGG AATAAGAGC AGGATGCTGC GGAATTC 1643

FIG.1B-4





FIG. 2

10/17






FIG. 4



12/17

GAATTCGCCA GCC ATG ACC CCG CAG CTT CTC CTG GCC CTT GTC CTC TGG 49

Met	Thr	Pro	Gln	Leu	Leu	Leu	Ala	Leu	Val	Leu	Trp
1				5					10		

GCC AGC TGC CCG CCC TGC AGT GGA AGG AAA GGG CCC CCA GCA GCT CTG 97

Ala	Ser	Cys	Pro	Pro	Cys	Ser	Gly	Arg	Lys	Gly	Pro	Pro	Ala	Ala	Leu
15							20						25		

ACA CTG CCC CCG GTG CAA TGC CGA GCC TCT CCG TAC CCG ATC GCC GTG 145

Thr	Leu	Pro	Arg	Val	Gln	Cys	Arg	Ala	Ser	Arg	Tyr	Pro	Ile	Ala	Val
30						35					40				

GAT TGC TCC TGG ACC CTG CCG CCT GCT CCA AAC TCC ACC AGC CCC GGT 193

Asp	Cys	Ser	Trp	Thr	Leu	Pro	Pro	Ala	Pro	Asn	Ser	Thr	Ser	Pro	Gly
45					50					55	CHO ###	###		60	

GTC CGT GGA TTG CGA CGT ACA GGC TCG GCA TGG CTG CCC GGG GCC ACA 241

Val	Arg	Gly	Leu	Arg	Arg	Thr	Gly	Ser	Ala	Trp	Leu	Pro	Gly	Ala	Thr
			65						70					75	

GCG TGG CCC TGC CTG CAG CAG ACG CCA ACG TCC ACC AGC TGC ACC ATC 289

Ala	Trp	Pro	Cys	Leu	Gln	Gln	Thr	Pro	Thr	Ser	Thr	Ser	Cys	Thr	Ile
			80					85					90		

ACG GAT GTC CAG CTG TTC TCC ATG GCT CCC TAC GTG CTC AAT GTC ACC 337

Thr	Asp	Val	Gln	Leu	Phe	Ser	Met	Ala	Pro	Tyr	Val	Leu	Asn	Val	Thr
		95					100					105	CHO ###	###	

GCC GTC CAC CCC TGG GGC TCC AGC AGC AGC TTC GTG CCT TTC ATA ACA 385

Ala	Val	His	Pro	Trp	Gly	Ser	Ser	Ser	Ser	Phe	Val	Pro	Phe	Ile	Thr
	110					115					120				

GAG CAC ATC ATC AAG CCC GAC CCT CCA GAA GGC GTG CGC CTA AGC CCC 433

Glu	His	Ile	Ile	Lys	Pro	Asp	Pro	Pro	Glu	Gly	Val	Arg	Leu	Ser	Pro
125					130					135				140	

FIG.5A

SUBSTITUTE SHEET (RULE 26)

13/17

CTC GCT GAG CGC CAC GTA CAG GTG CAG TGG GAG CCT CCC GGG TCC TGG 481  
 Leu Ala Glu Arg His Val Gln Val Gln Trp Glu Pro Pro Gly Ser Trp  
                     145                    150                    155

CCC TTC CCA GAG ATC TTC TCA CTG AAG TAC TGG ATC CGT TAC AAG CGT 529  
 Pro Phe Pro Glu Ile Phe Ser Leu Lys Tyr Trp Ile Arg Tyr Lys Arg  
                     160                    165                    170

CAG GGA GCT GCG CGC TTC CAC CGG GTG GGG CCC ATT GAA GCC ACG TCC 577  
 Gln Gly Ala Ala Arg Phe His Arg Val Gly Pro Ile Glu Ala Thr Ser  
                     175                    180                    185

TTC ATC CTC AGG GCT GTG CGG CCC CGA GCC AGG TAC TAC GTC CAA GTG 625  
 Phe Ile Leu Arg Ala Val Arg Pro Arg Ala Arg Tyr Tyr Val Gln Val  
                     190                    195                    200

GCG GCT CAG GAC CTC ACA GAC TAC GGG GAA CTG AGT GAC TGG AGT CTC 673  
 Ala Ala Gln Asp Leu Thr Asp Tyr Gly Glu Leu Ser Asp Trp Ser Leu  
                     205                    210                    215                    220

CCC GCC ACT GCC ACA ATG AGC CTG GGC AAG TAGCAAGGGC TTCCCGCTGC 723  
 Pro Ala Thr Ala Thr Met Ser Leu Gly Lys \*\*\*  
                     225                    230

CTCCAGACAG CACCTGGGTC CTCGCCACCC TAAGCCCGG GACACCTGTT GGAGGGCGGA 783

TGGGATCTGC CTAGCCTGGG CTGGAGTCCT TGCTTTGCTG CTGCTGAGCT GCCGGGCAAC 843

CTCAGATGAC CGACTTTTCC CTTTGAGCCT CAGTTTCTCT AGCTGAGAAA TGGAGATGTA 903

CTACTCTCTC CTTTACCTTT ACCTTTACCA CAGTGCAGGG CTGACTGAAC TGCTACTGTG 963

FIG.5B

SUBSTITUTE SHEET (RULE 26)

14/17

AGATATTTT TATTGTTAA TTAGAAAAGA ATTGTTGTTG GGCTGGCGC AGTGGATCGC 1023

ACCTGTAATC CCACTCACTG GGAAGCCGAC GTGGGTGGGT AGCTTGAGGC CAGGAGCTCG 1083

AAACCACTCC GGGCCACACA GCAAGACCCC ATCTCTAAAA AATTAATATA AATATAAAAT 1143

AAAAAAAAA AAAAGGAATT C 1164

FIG.5C





FIG. 6



17/17




FIG. 7B

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/09636

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) : C07H 21/02, 21/04; C12N 5/10; C12N 5/12

US CL : 536/24.32, 23.72; 435/240.2, 252.3; 530/350, 387.1, 388.3

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/24.32, 23.72; 435/240.2, 252.3; 530/350, 387.1, 388.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DNA DATA BASES GENBANK, EMBL, GENESEQ; AND PROTEIN DATA BASES PIR 35, SWISS-PROT 24, AND A-GENESEQ, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	Proceedings of the National Academy of Sciences, Vol. 84, issued May 1987, Wang et al., "Epstein-Barr virus nuclear antigen 2 specifically induces expression of the b-cell activation antigen CD23," pages 3452-3456, see page 3453.	9-11, 18, 19 ----- 13
Y	1988 Stratagene Catalog, page 39, see entire document.	13
A	Virology, Vol. 181, issued 1991, Alfieri et al., "Early events in Epstein-Barr Virus infection of human B lymphocytes," pages 595-608, see entire document.	1-26

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

Special categories of cited documents:		T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A	document defining the general state of the art which is not considered to be part of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E	earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	G	document member of the same patent family
O	document referring to an oral disclosure, use, exhibition or other means		
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

15 November 1993

Date of mailing of the international search report

14 JAN 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

SCOTT HOUTTEMAN

Telephone No. (703) 308-0196